CA2485006A1 - Camptothecin derivatives and polymeric conjugates thereof - Google Patents
Camptothecin derivatives and polymeric conjugates thereof Download PDFInfo
- Publication number
- CA2485006A1 CA2485006A1 CA002485006A CA2485006A CA2485006A1 CA 2485006 A1 CA2485006 A1 CA 2485006A1 CA 002485006 A CA002485006 A CA 002485006A CA 2485006 A CA2485006 A CA 2485006A CA 2485006 A1 CA2485006 A1 CA 2485006A1
- Authority
- CA
- Canada
- Prior art keywords
- substituted
- aryls
- group
- alkyls
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Abstract
Polymeric conjugates of camptothecin derivatives having increased circulating half-lives are disclosed. In preferred aspects, the E ring lactone of the camptothecin derivatives is opened and funtionalzed to allow attachment of a polymer such as PEG in the 17-or 20-position thereof. A representative example of such compound is (I) methods of preparing and using the same are also disclosed.
Description
CAMPTOTHECIN DERIVATIVES AND POLYMERIC
CONJUGATESTHEREOF
TECHNICAL FIELD
The present invention relates to polymeric derivatives of camptothecin and related topoisomerase inhibitor compounds. More particularly, the invention relates to camptothecin derivatives in which the E ring lactone has been modified to allow attachment of substantially non-antigenic polymers.
BACKGROUND OF THE INVENTION
Camptothecin is a water-insoluble cytotoxic alkaloid produced by Camptotheca accuminata trees indigenous to China and Nothapodytes foetida trees indigenous to India Camptothecin and related analogs are known to be potential anticancer agents and have demonstrated therapeutic activity in vitro and in vivo.
Over the years, various proposals have been made to increase the water solubility and/or therapeutic and pharmacokinetic properties of camptothecin analogs. One early attempt to increase the water solubility of camptothecin is disclosed in U.S. Patent No. 4,943,579 (hereinafter the '579 patent). The '579 patent discloses certain simple 20(S)-camptothecin amino acid esters in their salt forms as water soluble prodrugs. As evidenced by the data provided in Table 2 of the '579 patent, hydrolysis is rapid. Consequently, at physiologic pH, the insoluble base is rapidly generated after injection, binds to proteins and is quickly eliminated from the body before full therapeutic effect can be achieved. A related effort was directed to developing a water-soluble camptothecin sodium salt.
Unfortunately, the water-soluble sodium salt of camptothecin remained too toxic for clinical application (Gottlieb et al,. 1970 Cancer Chemother, Rep. 54, 461; Moertel et al,.
1972 ibid, 56, 95; Gottlieb et al., 1972 ibid, 56, 103).
Other attempts at improving the solubility of camptothecin analogs are provided by Greenwald et al. For example, commonly-assigned U.S. Patent No.
5,965,566 discloses camptothecin attached to a bifunctional PEG using an amino acid-based linkers. U.S. Patent No. 6,011,042 discloses polymeric derivatives of 10-hydroxycamptothecin. The PEG-derivatives provide the artisan with a water soluble prodrug which, upon administration, eventually liberate the parent compound in vivo. Prodrugs allow the artisan to modify the onset and/or duration of action of an agent in vivo and can modify the transportation, distribution or solubility of a drug in the body. Furthermore, prodrug formulations often reduce the toxicity and/or otherwise overcome difficulties encountered when administering pharmaceutical preparations.
The E-lactone ring is thought to be essential for anti-cancer activity.
Nonetheless, Sawada et al. have suggested in U.S. Patent No. 4,914,205 and Chem. Pharm. Bull. 41 (2) 310-313 (1993) prodrugs of camptothecin and the 7-ethyl derivative thereof having a modified E-lactone-ring. Specifically, the E-lactone ring is opened to provide 17-O-acyl derivatives and the authors demonstrated improved solubility of HCl salts thereof when compared to the native alkaloid. In spite of the increases in solubility demonstrated by the open lactone E-ring derivatives, further improvements have been sought. For example, after administration, the prodrug must be converted back into its active form in order to have biological (anticancer) activity. Consequently, these derivatives are highly dependent upon the hydrolysis of the respective hydroxyacids to free the 17-hydroxyl group in order to regenerate the E-ring lactone. Such conversions, however, are difficult to predict. It would be highly desirable to provide E-lactone ring modified camptothecin analogs with extended circulating half lives and more predictable rates of regenerating the closed lactone ring. The present invention addresses this need.
CONJUGATESTHEREOF
TECHNICAL FIELD
The present invention relates to polymeric derivatives of camptothecin and related topoisomerase inhibitor compounds. More particularly, the invention relates to camptothecin derivatives in which the E ring lactone has been modified to allow attachment of substantially non-antigenic polymers.
BACKGROUND OF THE INVENTION
Camptothecin is a water-insoluble cytotoxic alkaloid produced by Camptotheca accuminata trees indigenous to China and Nothapodytes foetida trees indigenous to India Camptothecin and related analogs are known to be potential anticancer agents and have demonstrated therapeutic activity in vitro and in vivo.
Over the years, various proposals have been made to increase the water solubility and/or therapeutic and pharmacokinetic properties of camptothecin analogs. One early attempt to increase the water solubility of camptothecin is disclosed in U.S. Patent No. 4,943,579 (hereinafter the '579 patent). The '579 patent discloses certain simple 20(S)-camptothecin amino acid esters in their salt forms as water soluble prodrugs. As evidenced by the data provided in Table 2 of the '579 patent, hydrolysis is rapid. Consequently, at physiologic pH, the insoluble base is rapidly generated after injection, binds to proteins and is quickly eliminated from the body before full therapeutic effect can be achieved. A related effort was directed to developing a water-soluble camptothecin sodium salt.
Unfortunately, the water-soluble sodium salt of camptothecin remained too toxic for clinical application (Gottlieb et al,. 1970 Cancer Chemother, Rep. 54, 461; Moertel et al,.
1972 ibid, 56, 95; Gottlieb et al., 1972 ibid, 56, 103).
Other attempts at improving the solubility of camptothecin analogs are provided by Greenwald et al. For example, commonly-assigned U.S. Patent No.
5,965,566 discloses camptothecin attached to a bifunctional PEG using an amino acid-based linkers. U.S. Patent No. 6,011,042 discloses polymeric derivatives of 10-hydroxycamptothecin. The PEG-derivatives provide the artisan with a water soluble prodrug which, upon administration, eventually liberate the parent compound in vivo. Prodrugs allow the artisan to modify the onset and/or duration of action of an agent in vivo and can modify the transportation, distribution or solubility of a drug in the body. Furthermore, prodrug formulations often reduce the toxicity and/or otherwise overcome difficulties encountered when administering pharmaceutical preparations.
The E-lactone ring is thought to be essential for anti-cancer activity.
Nonetheless, Sawada et al. have suggested in U.S. Patent No. 4,914,205 and Chem. Pharm. Bull. 41 (2) 310-313 (1993) prodrugs of camptothecin and the 7-ethyl derivative thereof having a modified E-lactone-ring. Specifically, the E-lactone ring is opened to provide 17-O-acyl derivatives and the authors demonstrated improved solubility of HCl salts thereof when compared to the native alkaloid. In spite of the increases in solubility demonstrated by the open lactone E-ring derivatives, further improvements have been sought. For example, after administration, the prodrug must be converted back into its active form in order to have biological (anticancer) activity. Consequently, these derivatives are highly dependent upon the hydrolysis of the respective hydroxyacids to free the 17-hydroxyl group in order to regenerate the E-ring lactone. Such conversions, however, are difficult to predict. It would be highly desirable to provide E-lactone ring modified camptothecin analogs with extended circulating half lives and more predictable rates of regenerating the closed lactone ring. The present invention addresses this need.
SUMMARY OF THE INVENTION
In one aspect of the invention, compounds of Formula (I) are provided:
(I) ;, Y~
\ ~~(Yz) a (~,) b A~
~O ~~
luu~~...
RI
OH ~~
wherein:
R~ is selected from the group consisting of amino acid residues, peptide residues containing from about 2 to about 10 amino acids, Y3-(Lz)P Az and Rz;
Y3 is O, S or NR3;
p is zero or one;
Lz is a bifunctional linker;
Y1 is O, S or NR4;
Yz is O, S, CRSR~ or NR~;
L1 is a bifunctional linker;
a and b are independently zero or one;
Ai and Az are independently selected from the group consisting of hydrogen, amino protecting groups, NRsR9, amino acid residues, peptide residues containing from about 2 to about 10 amino acids; polymeric residues, R,o, SR,1, NC(O)Riz;
D3 -D~ are independently selected from the group consisting of H, C1_g straight or branched alkyls, substituted C,_g straight or branched alkyls, aryls, substituted aryls, arylalkyls, substituted aryalkyls, C1_g alkylaryls, C1_g alkoxys, C,_s hydroxyalkyls, Ci-s aminoalkoxy, aryloxys, gycals, COZR13, R>a, nitro, cyano, halo, hydroxyl, amino, SRS, NR»R,~ or ORIg, where D4 and DS optionally, when taken together, form a saturated 3-7 membered heterocyclic ring which may contain O, S or NR,9 groups, where R,9 is hydrogen or a C1_~ alkyl;
Dg-Dlo are independently selected from the group consisting of H, C1_g straight or branched alkyls, substituted C,_g straight or branched alkyls, aryls, substituted aryls, arylalkyls, substituted aryalkyls, C1_g alkylaryls and C,_g hydroxyalkyls; and RZ_18 are independently selected from the group consisting of hydrogen, C1-s alkyls, C3-19 branched alkyls, C3-s cycloalkyls, C1-6 substituted alkyls, C3_8 substituted cyloalkyls, aryls, substituted aryls, aralkyls, C,_~
heteroalkyls, substituted C1_6 heteroalkyls, C1.6 alkoxy, phenoxy and Ci_s heteroalkoxy;
except that at least one of A, and AZ comprise a polymeric residue.
In another aspect of the invention there is provided bifunctional compounds that are formed when at least one of A1 and AZ comprises a polymeric residue and the polymeric residue is functionalized on both the alpha and omega termini to allow two equivalents of the camptothecin to be delivered per equivalent of the polymer which is preferably PEG. Such preferred compositions correspond to formulae (IIIa) and (IIIb) below:
D~
~D ~N G D V Y jn'2)a~~~)~ A' ~~
a ~ ,~ ~'z)e D
\O ~Y~ O 9 Da p~ (IIIa) Duo Vii, . CSR' G~~O N C _ ps OH\~ Rip D~ ~ B A 5.
N
OHO~\ pio ~ p , Ds °- -and .~~ O\ Da De D~
~O~N ~, B Ds O HOV,. Duo Da...
For purposes of the present invention, the term "residue" shall be understood to mean that portion of a camptothecin derivative or bifunctional spacer which remains after it has undergone a substitution reaction.
Methods of preparing the compositions of the invention and methods of treatment using the sane are also provided.
wherein all variables are as previously defined above.
For purposes of the present invention, the term "polymeric residue" or "PEG residue" shall each be understood to mean that portion of the polymer or PEG which remains after it has undergone a reaction with a heteroaromatic amine-containing compound.
For purposes of the present invention, the term "alkyl" shall be understood to include straight, branched, substituted, e.g. halo-, alkoxy-, nitro-, C1_iz alkyls, C3_g cycloalky(s or substituted cycloalkyls, etc.
For purposes of the present invention, the term "substituted" shall be understood to include adding or replacing one or more atoms contained within a functional group or compound with one or more different atoms.
For purposes of the present invention, substituted alkyls include carboxyalkyls, aminoalkyls, dialkylaminos, hydroxyalkyls and mercaptoalkyls;
substituted alkenyls include carboxyalkenyls, aminoalkenyls, dialkenylaminos, hydroxyalkenyls and mercaptoalkenyls; substituted alkynyls include carboxyalkynyls, aminoalkynyls, dialkynylaminos, hydroxyalkynyls and mercaptoalkynyls; substituted cycloalkyls include moieties such as 4-chlorocyclohexyl; aryls include moieties such as napthyl; substituted aryls include moieties such as 3-bromo-phenyl; aralkyls include moieties such as toluyl;
heteroalkyls include moieties such as ethylthiophene; substituted heteroalkyls include moieties such as 3-methoxy-thiophene; alkoxy includes moieties such as methoxy; and phenoxy includes moieties such as 3-nitrophenoxy. Halo- shall be understood to include fluoro, chloro, iodo and bromo.
The term "sufficient amounts" for purposes of the present invention shall mean an amount which achieves a therapeutic efl'ect as such effect is understood by those of ordinary skill in the art.
One advantage of the invention is that the artisan is provided with prodrugs of camptothecin derivatives with improved aqueous solubility.
Another advantage of the compounds of the invention is that in certain preferred embodiments, the releasble polymer not only extends the circulating life of the camptothecin derivative, but it also provides a means for controlling conversion of the open E-ring lactone back to the biologically active form.
This result is achieved by virtue of the fact that the open E-ring camptothecin derivative cannot hydrolyze into the closed E lactone ring until the polymer is released.
BRIEF DESCRIPTION OF THE DRAWINGS
Figures I-G schematically illustrate methods of forming compounds of the present invention which are described in the Examples.
A. FORMULA (I) In one preferred embodiment of the invention, there are provided compounds of the Formula (I):
(I) -C O
. D
~yY2) a W) ~ A~
~i III~~~~,.. C
RI
OH ~~
wherein:
Rl is selected from the group consisting of anuno acid residues, peptide residues containing from about 2 to about 10 amino acids, Y3-(LZ)p-AZ and R2;
Y3 is O, S or NR3;
p is zero or one;
L2 is a bifunctional linker;
Y~ is O, S or NRa;
Y2 is O, S, CRSR~ or NR~;
L1 is a bifunctional linker;
a and b are independently zero or one;
G
Ds Ch Do A1 and A2 are independently selected from the group consisting of hydrogen, amino protecting groups, NRgR9, amino acid residues, peptide residues containing from about 2 to about 10 amino acids; polymeric residues, RIO, SRII, NC(O)Rla;
D3 -D~ are independently selected from the group consisting of H, C1_s straight or branched alkyls, substituted CI.B straight or branched alkyls, aryls, substituted aryls, arylalkyls, substituted aryalkyls, Ci_g alkylaryls, C1_g alkoxys, CI_s hydroxyalky(s, C,_g aminoalkoxy, aryloxys, gycals, C02RI3, R14, nitro;
cyano, halo, hydroxyl, amino, SRIS, NR1~R1~ or ORIg, where D4 and DS optionally, when taken together, form a saturated 3-7 membered heterocyclic ring which may contain O, S or NR19 groups, where RIB is hydrogen or a C,_~ alkyl;
Ds-Dlo are independently selected from the group consisting of H, CI_s straight or branched alkyls, substituted C,_g straight or branched alkyls, aryls, substituted aryls, arylalkyls, substituted aryalkyls, CI_s alkylaryls and C1_8 hydroxyalkyls; and Rz_1g are independently selected from the group consisting of hydrogen, CIA alkyls, C3-19 branched alkyls, C3-g cycloalkyls, CI-~ substituted alkyls, C3_8 substituted cyloalkyls, aryls, substituted aryls, aralkyls, CI-6 heteroalkyls, substituted C1_6 heteroalkyls, CI_~ alkoxy, phenoxy and Cl_~ heteroalkoxy;
except that at least one of AI and AZ comprise a polymeric residue.
In many preferred aspects of the invention, one of A1 and AZ includes a polymer residue. The polymer residue optionally includes a capping group designated J herein. Within this aspect of the invention, when A, is a polymer residue, the capping group J is selected from among, for example, OH, NH2, SH, COzH, CI-~ alkyl moieties and Ila) DS ~~
w Alternatively, when R, is Y3-(LZ),; A2 in formula (I), and AZ is a polymer residue, the capping group J is selected from among, for example, OH, NH2, SH-, COzH, C1~ alkyl moieties and At-(Lt)b (''z) Ilb) -(LZ)-P
DS ~~
The preferred capping groups allow preferred compositions of (IIIa) and (IIIb), respectively, Ds D~ Da ~jIY2)a~Lt)b At ILI
C (~'z)fl D
O ~Yt O 9 D8 p~ (IIIa) Dto pn. C~Ri ~~O N C _ Ds off R~~ / N A 5, Dto \ v Da Da_..
and D7 ~ O Yt ~Y2ls l4,lb At yt D9 D
(IIIb) De ' ~ At-(Ltd (VZ)y ~ 8 ~ D
B C C~O~N ~.
A / D O ~~Ar-(L~-Y~ D \ B --N ~ ~ C Ys~~ ~ ° ° ~~ ~ N A DS~, D Dto ~~tnw' OH O O ~\\", Dto D4, .
to be formed, wherein all variables are as previously defined.
When LI and/or L2 include an amino acid residue, the amino acid can be selected from any of the known naturally-occurring L- amino acids is, e.g_, alanine, valine, leucine, isoleucine, glycine, serine, threonine, methionine, cysteine, phenylalanine, tyrosine, tryptophan, aspartic acid, glutamic acid, lysine, arginine, histidine, proline, and/or a combination thereof, to name but a few. When LI
and/or L2 include a peptide, the peptide ranges in size, for instance, from about 2 to about 10 amino acid residues. In one preferred embodiment, the peptide is Gly-Phe-Leu-. Alternatively, glycine can be added to the aforementioned trippeptide after leucine to form a 4 residue peptide.
The amino acid residues are preferably of the formula Ya -C-(CHZ~X' wherein X' is O, S or NR34, Y4 is 0, S or NR35, and f is a positive integer from about 1 to about 10, preferably 1; and R34 and R3s are independently selected from the same group as that which de1=tnes R3, but each is preferably H or lower alkyl.
Derivatives and analogs of the naturally occurring amino acids, as well as various art-known non-naturally occurring amino~acids (D or L), hydrophobic or non-hydrophobic, are also contemplated to be within the scope of the invention.
Simply by way of example, amino acid analogs and derivates include:
2-aminoadipic acid, 3-amino-adipic acid, beta-alanine, beta-aminopropionic acid, 2-aminobutyric acid, 4-amino-butyric acid, piperidinic acid, 6-aminocaproic acid, 2-aminoheptanoic acid,-2-aminoisobutyric acid, 3-aminoisobutyric acid, 2-aminopimelic acid, 2,4-diamino-butyric acid, desmosine, 2,2-diaminopimelic acid, 2,3-diaminopropionic acid, n-ethylglycine, N-ethylasparagine, 3-hydroxyproline, 4-hydroxyproline, isodesmo-sine, allo-isoleucine, N-methylglycine, sarcosine, N-methylisoleucine, G-N-methyl-lysine, N-methylvaline, norvaline, norleucine, ornithine, and others too numerous to mention, that are listed in 63 Fed. Reg., 29620, 29622, incorporated by reference herein.
Short peptides are, for example, peptides ranging from 2 to about 10, or more, amino acid residues, as mentioned supra.
Within most aspects of the invention, the following embodiments are preferred:
Y1 and Yz are each oxygen, RZ-R14 and D~ - Dlo are each hydrogen, L1 is selected from among (CHz)n .
(CHz)3~I-C(~) (CHz)3NH--NI-I(CH2CH20)n(CHz)n~z2-.
-NH(CH2CH20)", -NH(Cz3R24)nV-.
-C(~)(~-R2iR24)nNHC(U)((,-R25R26)q~27-, -C(0)0(CHIz)n0-, -C(O)(CR~R24)n~27-~
-C(O)NH(CH2CH20)"(CHz)nNRz7-, -C(O)O-(CH2CH20)nNRz7-~
-C(O)NH(CR23R24)n~'>
-C(~)~(CR23R24)n~-~
-C(O)NI-I(CH2CH20)", -NH(CR23R24)n ~ ' ~ (CR24R23)n0- and ~Rzs -~(CR23R24)n ~ ~ (CR24R23)~NR2~->
wherein R2z_z7 are independently selected from the group consisting of hydrogen, C1-6 alkyls, C3-12 branched alkyls, C3_s cycloalkyls, C1_~ substituted alkyls, C3_g substituted cycloalkyls, aryls substituted aryls, aralkyls, C1_~
heteroalkyls, substituted C1_~ heteroalkyls, C1_~ alkoxy, phenoxy and C1~ heteroalkoxy;
R2g is selected from the group consisting of hydrogen, C1.~ alkyls, C3_,2 branched alkyls, C3_8 cycloalkyls, C,_6 substituted alkyls, C3_g substituted cycloalkyls, aryls substituted aryls, aralkyls, C,_6 heteroalkyls, substituted C1.~ heteroalkyls, C1-~ alkoxy, phenoxy and C,_~ heteroalkoxy, NOz, haloalkyl and halogen; and n and q are independently selected positive integers.
L2 is preferably selected from among:
(CHz)j (CH2CHz0)z(CHz)zNH, -NH(CHZCH20)j(CHz)~NRz9-, -NH(CH2CH20)j-, -~(CR3oR31)j~-~
-C(~)(CR3oR31)jNHC(O)(CR3zR33)jNRz9--C(O)O(CHz~O-, -C(~)(CR30R31)jNR29-, -C(0)NH(CHzCHzO)j(CHz)kNRz9-~
-C(O)O-(CHZCH20)jNRz9-, -C(0)~(CR3oR31)j0-, -C(0)0(CR3oR3Oj0-~
-C(O)NH(CH2CH20)j-, -~(CR3oR31)j / ~ (CR3pR31)k~- and -~(CR30R31)j ~ / ~ (CR3oR3OkNR29-~
wherein Rz9_33 are independently selected from the group consisting of hydrogen, CL~ alkyls, C3_12 branched alkyls, C3_s cycloalkyls, C,_~ substituted alkyls, C3_8 substituted cycloalkyls, aryls substituted aryls, aralkyls, C1_~
heteroalkyls, substituted C1~ heteroalkyls, C1_6 alkoxy, phenoxy and C,_~ heteroalkoxy;
R34 is selected from the group consisting of hydrogen, CI_6 alkyls, C3-12 branched alkyls, C3_g cycloalkyls, C1-s substituted alkyls, C3_g substituted cycloalkyls, aryls substituted aryls, aralkyls, C1~ heteroalkyls, substituted C1~ heteroalkyls, C,_~ alkoxy, phenoxy and C1_~ heteroalkoxy, NOz, haloalkyl and halogen; and j and k are independently selected positive integers.
B. SUBSTANTIALLY NON-ANTIGENIC POLYMERS
As stated above, A1 and Az can comprise polymer residues. The polymer residues are preferably water soluble and substantially non-antigenic.
Particularly preferred polymers useful in the compositions of the present invention include polyalkylene oxides such as polyethylene glycol. The polymer residues optionally the previously mentioned capping groups, designated J, which allows a bifunctional or bis-polymer system to be formed.
In those aspects of the invention where A1 includes the polyethylene glycol residue, the PEG derivatives can be selected from the following non-limiting list:
-J-O-(CH2CH20)X , J-O-(CHZCH20)X CHZC(O)-O-, J-O-(CH~CHzO)X CHzCH2 NRZO-, J-O-(CHZCI-hO)X CH2CH2 SH-, -O-C(O)CH2-O-(CHZCHZO)X CHZC(O)-O-, -NR2oCH2CH2-O-(CH2CH20)X-CH2CH2 NRZO-, and -SHCH2CH2-O-(CH2CH20),; CH2CHz SH-, wherein:
x is the degree of polymerization;
RZO is selected from the group consisting of hydrogen, C1~ alkyls, C3_~z branched alkyls, C3_8 cycloalkyls, C1_~ substituted alkyls, C3_8 substituted cyloalkyls, aryls substituted aryls, aralkyls, C1_~ heteroalkyls, substituted Cm heteroalkyls, C~_6 alkoxy, phenoxy and C1_~ heteroalkoxy and J is a capping group.
Similarly, in those aspects of the invention where AZ includes the polyethylene glycol residue, the PEG derivatives can be selected from the following non-limiting list:
of J-0-(CHZCH20)X~ -J-O-(CH2CH20)X CH2C(O)-O-, J-O-(CH2CH20)X CH2CI-h NRz,-, J-O-(CH2CH20)x-CH2CH2 SH-, -O-C(O)CH2-O-(CH2CH20)X CH2C(O)-O-, -NR21CH2CH2-O-(CH2CH20)X CH2CH2 NRza, and -SHCH2CH2-O-(CH2CH20)x-CH2CH2 SH-, wherein:
x is the degree of polymerization;
Rz, is selected from the group consisting of hydrogen, C1-~ alkyls, C3-12 branched alkyls, C3-s cycloalkyls, C1_~ substituted alkyls, C3_s substituted cyloalkyls, aryls substituted aryls, aralkyls, C,-~ heteroalkyls, substituted C1~ heteroalkyls, C1_~ alkoxy, phenoxy and C1_~ heteroalkoxy and J is a capping group.
For the purpose of the present invention the structure:
-O-~ CH2CH20 x wherein x is a positive integer, is referred to as PEG throughout the application.
The degree of polymerization for the polymer (x) can be from about 10 to about 2,300. This represents the number of repeating units in the polymer chain and is dependent on the molecular weight of the polymer. In certain preferred aspects, the amount of polymerization is preferably sufficient to provide the polymer with a molecular weight of at least about 20,000 daltons. Since the ethylene glycol monomer has a molecular weight of 44, (x) is preferably at least about 454. The (J) moiety is a capping group as defined herein, i.e. a group which is found on the terminal of the polymer and, in some aspects, can be selected from any of NH2, OH, SH-, COZH, C1_~ alkyls or other PEG terminal activating groups, as such groups are understood by those of ordinary skill.
Also useful are polypropylene glycols, branched PEG derivatives such as those described in commonly-assigned U.S. Patent No. S,G43,575, "star-PEG's"
and multi-armed PEG's such as those described in Shearwater Corporation's 2001 catalog "Polyethylene Glycol and Derivatives for Biomedical Application". The disclosure of each of the foregoing is incorporated herein by reference. It will be understood that the water-soluble polymer can be functionalized for attachment to the bifunctional linkage groups if required without undue experimentation.
In many aspects of the present invention, bis-activated polyethylene glycols are preferred when di- or multi-substituted polymer conjugates are desired.
Alternatively, polyethylene glycols (PEG'S), mono-activated, C1-4 alkyl-terminated polyalkylene oxides (PAO's) such as mono-methyl-terminated polyethylene glycols (mPEG's) are preferred when mono-substituted polymers are desired.
In order to provide the desired hydrolyzable linkage, mono- or di-acid activated polymers such as PEG acids or PEG diacids can be used as well as mono-or di-PEG amines and mono- or di-PEG diols. Suitable PAO acids can be synthesized by first converting CH30-PEG-OH (mPEG-OH) to an ethyl ester followed by saponification. See also Gehrhardt, H., et al. Polymer Bulletin 18: 487 (1987) and Veronese, F.M., et al., J. Controlled Release 10; 145 (1989).
Alternatively, the PAO-acid can be synthesized by converting mPEG-OH into a t-butyl ester followed by acid cleavage. See, for example, commonly assigned U.S. Patent No. 5,605,976. The disclosures of each of the foregoing are incorporated by reference herein.
Although PAO's and .PEG'S can vary substantially in average molecular weight, the polymer portion of the prodrug is at least about 20,000 Da average in most aspects of the invention. Preferably, the polymer portion of the compositions has a weight average molecular weight of from about 20,000 Da to about 100,000 Da and more preferably from about 25,000 Da to about 60,000 Da. The average molecular weight of the polymer selected for inclusion in the prodrug must be sufficient so as to provide sufficient circulation of the prodrug before hydrolysis of the linker.
The polymeric substances included herein are preferably water-soluble at room temperature. A non-limiting list of such polymers include polyalkylene oxide homopolymers such as polyethylene glycol (PEG) or polypropylene glycols, polyoxyethylenated polyols, copolymers thereof and block copolymers thereof, provided that the water solubility of the block copolymers is maintained.
In a further embodiment, and as an alternative to PAO-based polymers, A1 and Az can optionally comprise one or more other effectively non-antigenic materials such as dextran, polyvinyl alcohols, carbohydrate-based polymers, hydroxypropylmeth-acrylamide (HPMA), polyalkylene oxides, and/or copolymers thereof. See also commonly-assigned U.S. Patent No, 6,153,655, the contents of which are incorporated herein by reference. It will be understood by those of ordinary skill that the same type of activation is employed as described herein as for PAO's such as PEG. Those of ordinary skill in the art will further realize that the foregoing list is merely illustrative and that all polymeric materials having the qualities described herein are contemplated. For purposes of the present invention, "effectively non-antigenic" and "substantially non-antigenic" shall be understood to include all polymeric materials understood in the art as being substantially non-toxic and not eliciting an appreciable immune response in mammals.
It will be clear from the foregoing that other polyalkylene oxide derivatives of the foregoing, such as the polypropylene glycol acids, etc., as well as other bi-functional linking groups are also contemplated.
C. CAMPTOTHECIN AND CAMPTOTHECIN ANALOGS
Camptothecin and certain related analogues and derivatives share the structure:
io;
,ti From this core structure, various derivatives are known. For example, the A
ring in either or both of the 10- and 11- positions can be substituted with an OH. The A
ring can also be substituted in the 9-position with a straight or branched C1_3o alkyl or C1_,~ alkoxy, optionally linked to the ring by a heteroatom i.e. O or S.
The B
ring can be substituted in the 7-position with a straight or branched C~_3o alkyl or substituted alkyl-, Cs_s cycloalkyl, C~_3o alkoxy, phenyl alkyl, etc., alkyl carbamate, alkyl carbazides, phenyl hydrazine derivatives, amino, aminoalkyl, aralkyl, etc.
Other substitutions are possible in the C, D and E rings. See, for example, U.S. Pat.
Nos. 5,004,758, 4,943,579, Re 32,518, 4,894,456, 5,225, 5,053,512, 4,981,968, 5,049,668, 5,106,742, 5,180,722, 5,244,903, 5,227,380, 5,122,606, 5,122,526, and 5,340,817, the contents of each of which are incorporated herein by reference.
In most aspects of the invention, the camptothecin derivatives which are employed in the formation of the compositions of the present invention are generally of the formula m E
luu~~,.. C
OH ~~
wherein:
D3 -D~ are independently selected from the group consisting of H, C,_8 straight or branched alkyls, substituted C,_g straight or branched alkyls, aryls, substituted aryls, arylalkyls, substituted aryalkyls, C,-g alkylaryls, C1_g alkoxys, C,-s hydroxyalkyls, C,_s aminoalkoxy, aryloxys, gycals, COzR,3, R14, vitro, cyano, halo, hydroxyl, amino, SR,S, NR1~R,~ or OR,g, where D4 and DS optionally, when taken together, form a saturated 3-7 membered heterocyclic ring which may contain O, S or NR,9 groups, where R,9 is hydrogen or a C,_6 alkyl;
Dg-D,o are independently selected from the group consisting of H, C,-g straight or branched alkyls, substituted C,_s straight or branched alkyls, aryls, substituted aryls, arylalkyls, substituted aryalkyls, C,-s alkylaryls and C,_s hydroxyalkyls; and Rg_,g are independently selected from the group consisting of hydrogen, C1_6 alkyls, C3_,9 branched alkyls, C3_8 cycloalkyls, C,_~ substituted alkyls, C3_s substituted cyloalkyls, aryls, substituted aryls, aralkyls, C,~
heteroalkyls>
substituted C,.s heteroalkyls, C,-6 alkoxy, phenoxy and C,_6 heteroalkoxy.
In other preferred aspects of the invention, the following can be used:
irinotecan H
iopotecan Still further camptothecin analogs which can be used in the practice of the present invention include, 10,11-oxycamptothecin, 10,11-methylene dioxycamptothecin, 7-ethylcamptothecin, 9-amino-camptothecin, to name but a few.
Those of ordinary skill will realize that the foregoing is merely illustrative of the camptothecin derivatives useful in practicing the present invention.
The only limitations on the camptothecin derivatives useful in the invention is that the specific derivative must be capable of undergoing the opening of the E-lactone ring, allowing a polymer to be attached thereto and, after administration, allowing hydrolysis to occur which allows the E-lactone ring to be re-formed in vivo.
D. SYNTHESIS OF THE CAMPTOTHECIN-POLYMERIC
PRODRUGS
Synthesis of specific representative polymer prodrugs is set forth in the Examples. Generally, however, in one preferred method of preparing the prodrug transport systems of the present invention, the E-lactone ring is opened, a capped bifunctional linker is attached at the 17-position of the open lactone ring, the blocking group is removed and followed by PEGylation with appropriate solvent and coupling agent, if required. The lactone ring can be opened using known techniques such as by dissolving the camptothecin derivative in N,N
dimethylethylenediamine (2 in the examples) or in isopropylamine (9 in the examples) or other suitable reagent solvents containing a primary amine and heating the reaction solution for a sufficient amount of time to allow the ring to be opened.
Once the E ring has been opened, the artisan is provided with a camptothecin derivative of the formula:
(t~) \OH
11~~~~"..
OH ~~
wherein:
Rl is selected from the group consisting of amino acid residues, peptide residues containing from about 2 to about 10 amino acids, Y3-(Lz)n AZ and R2;
Y3 is O, S or NR3;
p is zero or one;
L2 is a bifunctional linker;
A2 is selected from the group consisting of hydrogen, amino protecting groups, NRaR9, amino acid residues, peptide residues containing from about 2 to about amino acids; polymeric residues, Rlo, SCRII, NC(O)R12;
D3-D~ are independently selected from the group consisting of H, C1_s straight or branched alkyls, substituted C1_8 straight or branched alkyls, aryls, substituted aryls, arylalkyls, substituted aryalkyls, C1_s alkylaryls, C~_g alkoxys, C~_8 hydroxyalkyls, Ci-s aminoalkoxy, aryloxys, gycals, COzR,3, R14, vitro, cyano, halo, hydroxyl, amino, SR,S, NR,~RI~ or OR,g, where D4 and DS optionally, when taken together, form a saturated 3-7 membered heterocyclic ring which may contain O, S or NR~9 groups, where R19 is hydrogen or a C~_6 alkyl;
Ds-Duo are independently selected from the group consisting of H, C1_8 straight or branched alkyls, substituted C,_s straight or branched alkyls, aryls, substituted aryls, arylalkyls, substituted aryalkyls, C1_g alkylaryls and C1_g hydroxyalkyls; and R2_,g are independently selected from the group consisting of hydrogen, C1~ alkyls, C3-19 branched alkyls, Cs_s cycloalkyls, C1_~ substituted alkyls, C3_8 substituted cyloalkyls, aryls, substituted aryls, aralkyls, C,_~
heteroalkyls, substituted C» heteroalkyls, C1-6 alkoxy, phenoxy and C~_s heteroalkoxy;
which is then reacted with a blocked bifunctional spacer to form a protected intermediate. This intermediate is then deblocked and reacted with an activated polymer under conditions sufT'icient to cause a polymeric conjugate to be formed.
A non-limiting list of activated polymers include bis-succinimidyl carbonate activated PEG (SC-PEG), bis-thiazolidine-2-thione activated PEG (T-PEG), N-hydroxyphthalamidyl carbonate activated PEG (BSC-PEG), see commonly assigned USSN 09/823,296, the disclosure of which is incorporated herein by reference, succinimidyl succinate activated PEG (SS-PEG), imidazole-activated PEG (PEG-IMD), bis-carboxylic acid- PEG (PEG-COZH) and mono-activated PEG's such as those found in, for example, in the aforementioned Shearwater Catalog.
Conjugation of the intermediate to the PEG residue can be carried out in the presence of a coupling agent. A non-limiting list of suitable coupling agents include 1,3-diisopropylcarbodiimide (DIPC), any suitable dialkyl carbodiimide, 2-halo-1-alkyl-pyridinium.halides (Mukaiyama reagents), 1-(3-dimethylamino-propyl)-3-ethyl carbodiimide (EDC), propane phosphonic acid cyclic anhydride (PPACA) and phenyl dichlorophosphates, etc. which are available, for example from commercial sources such as Sigma-Aldrich Chemical, or synthesized using known techniques.
Preferably the substituents are reacted in an inert solvent such as tetrahydrofuran (THF), acetonitrile (CH3CN), methylene chloride (DCM), chloroform (CHC13), dimethylformamide (DMF) or mixtures thereof. The reaction is preferably conducted in the presence of a base, such as dimethylaminopyridine (DMAP), diisopropyl ethylamine, pyridine, triethylamine, KOH, potassium t-butoxide and NaOH, etc. and at a temperature from 0° C up to about 22° C (room temperature).
In an alternative embodiment, the compositions of the present invention are prepared by using the blocked bifunctional spacer to open the E-lactone ring in an inert solvent, acylating the 17-position OH group with, for example acetic or butyric anhydride, debloching the bifunctional spacer and attaching the polymer.
Specifically, the reaction involves reacting a compound of the formula -C O
(V) .. Da uu""..
OH ~~
wherein:
D3 -D~ are independently selected from the group consisting of H, C1_8 straight or branched alkyls, substituted C1_g straight or branched alkyls, aryls, substituted aryls, arylalkyls, substituted aryalkyls, C,_s alkylaryls, C,_s alkoxys, C,_8 hydroxyalkyls, C1_g aminoalkoxy, aryloxys, gycals, C02R~3, R,4, nitro, cyano, halo, hydroxyl, amino, SR,S, NR,~R» or OR,B, where D4 and DS optionally, when taken together, form a saturated 3-7 membered heterocyclic ring which may contain O, S or NR,9 groups, where R,~ is hydrogen or a C1_6 alkyl;
D8-Dlo are independently selected from the group consisting of H, C1_8 straight or branched alkyls, substituted C~_s straight or branched alkyls, aryls, substituted aryls, arylalkyls, substituted aryalkyls, C1_g alkylaryls and C1_g hydroxyalkyls; and Rg_I8 are independently selected from the group consisting of hydrogen, CI_~ alkyls, C3_19 branched alkyls, C3_g cycloalkyls, CI_~ substituted alkyls, C3_ssubstituted cyloalkyls, aryls, substituted aryls, aralkyls, CL~
heteroalkyls, substituted C1~ heteroalkyls, CI-6 alkoxy, phenoxy and CI_6 heteroalkoxy;
with a blocked bifunctional spacer in an inert solvent under conditions sufficient to open the E lactone and form a blocked intermediate of formula (VI) ~C
._Da Rss wherein R35 is a residue of a blocked bifunctional spacer;
b) acylating the CIA hydroxyl of the blocked intermediate, and c) deprotecting the blocked intermediate and reacting it with an activated polymer under conditions sufficient to cause a polymeric conjugate to be formed.
Regardless of the synthesis selected, some of the preferred compounds which result from the synthetic techniques described herein include:
,..o:
~2)a(L~)b A' (L~~ (~'2)e D
O 9 D8 ~ (IIIa) .O N C _ Ds D B
R~~ ~ N A 5.
Duo , D3 ~4_.
and pg Y~ ~~4~1e A~
(IIIb) D6 D7 p ~~(Y2~, A~_(L~~ (v~\~~ p D9 pe D~
C N ~ w N pe 8 p ~ p p C
C Y3~~~zlpAYI~~Y~C ~ N~DS,, N ~ ~_ '~_D~
Da .
Dz D pH p p Hp p ~ _.
where all variables are as previously defined and O
O p NH-~--PEG
N N O-~ ~/
O
O
HO
NH~NMey , O
~O~NH~PEG
\'O
Y
O O
N \ / O-ll-CH3 HO O O
N~O~O~NH~--PEG
H
j N_ O O~~O~NH-~L--O-~CHZ-CHz-O-~-II-N~p O N i i N ~ / O O _ \ / wN~~
O
HO .. ...OH and NH' / ~NH
where PEG = Me-0-(CHZCHzO)X or -O-(CHzCH20)X .
H H
E. METHODS OF TREATMENT
Another aspect of the present invention provides methods of treatment for various medical conditions, including topoisomerase inhibitor-related diseases in mammals. The methods include administering to the mammal in need of such treatment, an effective amount of a prodrug, of a camptothecin, camptothecin derivative, camptothecin analog and/or a mixture thereof, such as,those described herein. The compositions are useful for, among other things, treating neoplastic disease, reducing tumor burden, preventing metastasis of neoplasms and preventing recurrences of tumor/neoplastic growths in mammals.
The amount of the inventive composition administered will depend upon several factors, including potency of the parent molecule included therein and specific disease being treated. Generally, the amount of prodrug used in the treatment methods is that amount which effectively achieves the desired therapeutic result in mammals. Naturally, the dosages of the various prodrug compounds will vary somewhat depending upon the parent compound, rate of in vivo hydrolysis of the open E ring, the molecular weight of the polymer used, if any, etc. In general, dosing is based upon the amount of native (unmodified E-lactone ring) camptothecin or derivative thereof The camptothecin and derivatives of camptothecin are generally administered in amounts ranging from about 5 to about 500 mg/m2 per day. The range set forth above is illustrative and those skilled in the art will determine the optimal dosing of the prodrug selected based on clinical experience and the treatment indication.
The compositions, including prodrugs, of the present invention can be included in one or more suitable pharmaceutical compositions for administration to mammals. The pharmaceutical compositions may be in the form of a solution, suspension, tablet, capsule or the like, prepared according to methods well known in the art. It is also contemplated that administration of such compositions may be by the oral, inhalation and/or parenteral routes depending upon the needs of the artisan. A solution and/or suspension of the composition may be utilized, for example, as a carrier vehicle for injection or infiltration of the composition by any art la~own methods, e.g., by intravenous, intramuscular, subdermal injection and the like. Such administration may also be by infusion into a body space or cavity, as well as by inhalation and/or intranasal routes. 1n preferred aspects of the invention, however, the prodrugs are parenterally administered to mammals in need thereof.
EXAMPLES
The following examples serve to provide further appreciation of the invention but are not meant in any way to restrict the effective scope of the invention. All compounds mentioned in the following examples are numbered with reference to Figs 1-6.
General Procedures. All reactions were run under an atmosphere of dry nitrogen or argon. Commercial reagents were used without further purification. All PEG
compounds were 40kDa and were dried under vacuum or by azeotropic distillation from toluene prior to use. '3C NMR spectra were obtained at 75.46 MHz using a Varian Mercury 300 NMR spectrometer and deuterated chloroform as the solvent unless otherwise specified. Chemical shifts (8) are reported in parts per million (ppm) downfield from tetramethylsilane (TMS). All PEG conjugated compounds were dissolved in saline for injection prior to in vivo drug treatments and were given as their camptothecin equivalents (absolute amount of camptothecin given).
HPLC method. The reaction mixtures and the purity of intermediates and final products were monitored by a Beckman Coulter System Gold' HPLC instrument employing a ZOBAX'~ 300 SB C-8 reversed phase column (I50 x 4.6 mm) or a Phenomenex Jupiter 300A C18 reversed phase column (150 x 4.6 mm) with a multiwavelength UV detector, using a gradient of 30-90 % of acetonitrile in 0.5 trifluoroacetic acid (TFA) at a flow rate of 1 mL/min.
Example 1 Compound 5. Camptothecin (1) (1.44 g, 4.14 mmol) was dissolved in N,N-dimethylethylenediamine (2) (IS mL) and the reaction solution was heated at 50 °C for 2 hours. The solvent was removed under reduced pressure and the resulting solid washed with ether to give 3, which was suspended with dimethylamino-pyridine (DMAP, 1.0 g, 8.88 mmol) and 4 (1.3 g, 4.44 mmol) in anhydrous methylene chloride (DCM, 10 mL). The resulting reaction mixture was refluxed for 4 hours and then stirred at room temperature for 12 hours, washed with O.1N
HCI, dried with MgS04, filtered, and solvent evaporated under reduced pressure.
The crude material was purif ed on silica gel column to give 5 (0.080 g, 0.13 mmol, 3 %). '3C NMR (67.8 MHz, CDCI~) b 167.26, 157.15, 155.77, 153.69, 152.18, 148.76, 146.33, 145.71, 131.14, 130.65, 129.56, 128.37, 128.10, 128.02, 120.10, 95.82, 79.14, 77.83, 77.20, 67.01, GG.50, 50.03, 36.97, 31.84, 29.01, 28.37, 25.59, 7.73.
Example 2 Compound G. To a solution of 5 (0.080 g, 0.13 mmol) in DCM (1 mL) cooled in an ice bath, trifluoroacetic acid (TFA, 1 mL) was added drop-wise and stirred for min. 'The solvents were then removed under reduced pressure to give 6 (0.080 g, 0.13 mmol, 100 %). '3C NMR (67.8 MHz, CDC13) 8 167.50, 157.01, 153.95, 146.42, 145.31, 143.81, 134.69, 132.80, 129.26, 129.08, 128.52, 126.56, 120.92, 15 98.92, 78.27, 77.21, G6.G9, 65.27, 50.47, 37.15, 31.33, 26.55, 25.58, 7.53.
Example 3a Compound 8~. A solution of G (0.080 g, 0.13 mmol), 7a (1.50 g, 0.037 mmol), and DMAP (0.031 g, 0.25 mmol) in DCM (8 mL) was stirred at room temperature for 12 hours. The reaction mixture was washed with O.1N HCI (2x10 mL) and the 20 organic layer evaporated under reduced pressure. The solid residue was crystallized from isopropyl alcohol (IPA, 30 mL) to yield 8a (1.2 g, 0.029 mmol, 79 %). '3C NMR (67.8 MHz, CDCI3) 8 166.41, 156.36, 155.64, 152.92, 151.50, 148.01, 145.76, 144.89, 130.76, 129.90, 128.84, 127.95, 127.58, 127.29, 119.31, 94.90, 67.0-73.5 (PEG), 66.29, 65.78, 63.05, 49.46, 36.69, 31.12, 28.39, 7.14.
Example 3b Compound 8b. The procedure of Example 3~ is followed, except that PEG-C02H
7b (1.5 g, 0.037 mmol) and 2 equivalents of EDC is used in place of 7a to form an amide-linked PEG conjugate.
Example 4 Compound 11. 1 (1.44g, 4.14 mmol) was dissolved in isopropylamine 9 (35m1) and the solution refluxed for 1.5 hours. The solvent was removed under reduced pressure and the resulting solid washed with ether to give 10, which was suspended with DMAP (0.29 g, 2.36 mmol) and 4 (0.36 g, 1.18 mmol) in anhydrous chloroform (2 mL). The resulting reaction mixture was heated at 60 °C
for 1 hour, washed with O.1N HCI, dried (MgS04), filtered, and the solvent evaporated under reduced pressure. The crude material was purif ed by column chromatography to give 11 (0.068 g, 0.11 mmol, 3 %). '3C NMR (67.8 MHz, CDC13) 8 171.26, 161.43, 156.41, 155.92, 155.33, 152.09, 148.46, 144.57, 130.66, 130.22, 129.37, 128.37, 127.90, 127.71, 123.90, 100.57, 79.17, 77.20, 75.92, 65.22, 62.13, 50.27, 41.72, 37.09, 32.87, 29.33, 28.46, 22.74, 22.44, 7.90.
Example 5 Compound 12. To a solution of compound 11 (0. 68 g, 0.11 mmol) in DCM (1 mL), cooled in an ice bath, was added TFA (1 mL) drop-wise and the solution stirred for 2 hours. The solvents were removed under reduced pressure to give (0.067 g, 0.11 mmol, 100 %). '3C NMR (67.8 MHz, CDCl3/CD30D) b 171.74, 161.75, 157.19, 154.76, 152.01,.148.27, 144.55, 131.41, 130.62, 128.90, 128.58, 128.08, 127.91, 123.53, 101.24, 78.50, 64.99, 62.33, 50.23, 41.55, 37.06, 32.19, 26.35, 22.32, 22.00, 7.55.
Example 6a Compound 13a. A solution of 12 (0.067 g, 0.11 mmol), 7a, (1.30 g, 0.032 mmol), and DMAP (0.027 g, 0.22 mmol) in DCM (8 mL) was stirred at room temperature for 12 hours. The reaction mixture was washed with O.1N HC1 (2x10 mL) and the organic layer evaporated under reduced pressure. The solid residue was crystallized from IPA (30 mL) to yield 13a (1.1 g, 0.028 mmol, 86 %). '3C NMR
(67.8 MHz, CDCl3) 8 170.64, 160.74, 155.82, 154.54, 151.65, 147.90, 144.02, 134.37, 130.35, 129.57, 128.77, 128.03, 127.43, 127.20, 99.61, 67.0-73.5 (PEG), 64.63, 63.23, 61.49, 49.71, 41.07, 37.02, 32.11, 28.74, 22.20, 21.84, 7.41.
Example Gb Compound 13b. The procedure of Example 6a is followed, except that PEG-COzH
7b (1.5 g, 0.037 mmol) is used with 2 equivalents of EDC in place of 7a to form an amide-linked PEG conjugate.
Example 7 Compound 16. A mixture of 1 (0.34 g, 0.97 mmol), 14 (4.7 g, 19 mmol), and diisopropylethylamine (DIEA, 3.3 mL, 1.4 mmol) in dimethylformamide (DMF, 7 mL) was heated at 70 °C for 48 hours and a clear solution was obtained.
The solvent was removed under reduced pressure, and the resulting solid washed with hexane and then ether to give 15 which was suspended in anhydrous DCM (10 mL) and cooled to 0 °C in an ice bath. Acetic anhydride (0.10 mL, 1.1 mmol) and DMAP (0.057 g, 0.47 mmol) were added to the above suspension and stirred for 3 hours at ambient temperature. The reaction mixture was washed with 0.1 N
sodium bicarbonate (10 mL), and the organic layer evaporated under reduced pressure. The residue was purif ed on silica gel column to give pure 16 (0.25 g, 0.39 mmol, 40 %). ~3C NMR (67.8 MHz, CDCl3) 8 172.19, 170.95, 161.38, 156.80, 155.91, 151.42, 148.04, 144.05, 130.42, 130.00, 128.92, 127.89, 127.68, 127.58, 127.26, 124.77, 100.60, 79.15, 78.55, 70.14, 69.37, 58.78, 50.23, 40.33, 39.04, 32.93, 28.40, 20.99, 7.92.
Example 8 Compound 17. To a solution of 1G (0.12 g, 0.19 mmol) in DCM (1 mL) cooled in an ice bath was added TFA (1 mL) dropwise and stirred for 30 minutes. Solvent was removed under reduced pressure to give 6 (0.12 g, 0.19 mmol, 100 %). '3C
NMR (67.8 MHz, CDC13) 8 173.01, 172.22, 161.33, 157.08, 149.97, 146.13, 142.92, 132.94, 131.47, 128.55, 128.40, 128.10, 127.67, 127.23, 125.13, 117.41, 113.59, 102.62, 78.65, 70.19, 69.37, 66.48, 58.63, 50.67, 40.06, 39.28, 32.68, 20.78, 7.62.
Example 9a Compound 18a. A solution of 17 (0.050 g, 0.090 mmol), 7a (1.20 g, 0.030 mmol), and DMAP (0.022 g, 0.18 mmol) in DCM (G mL) was stirred at room temperature for 12 hours. The reaction mixture was washed with 0.1N HCI (2x10 mL) and the organic layer evaporated under reduced pressure. The solid residue was crystallized from IPA (30 mL) to yield 18a (1.1 g, 0.027 mmol, 89 %). '3C NMR
(67.8 MHz, CDC13) 8 171.82, 170.32, 160.71, 155.75, 155.23, 151.59, 147.82, 143.79, 134.41, 130.30, 129.55, 128.70, 127.90, 127.42, 127.11, 124.07, 99.59, 67.0-73.5 (PEG), 63.14, 58.50, 49.61, 40.17, 38.58, 32.14, 20.48, 7.38.
Example 9b Compound 186. The procedure of Example 9a is followed, except that PEG-COZH 7b (1.5 g, 0.037 mmol) is used with 2 equivalents of EDC in place of 7a to form an amide-linked PEG conjugate.
Example 10 The efficacy of open-form ca~nptothecin analogs against a subcutaneous human mammary carcinoma (MX-1) grown in nude mice was determined as follows.
Following at least one week of acclimation, tumors were established by implanting small tumor fragments from donor mice into a single subcutaneous site, on the left axillary flank region of nude mice. The tumor implantation site was observed twice weekly and measured once palpable. The tumor volume for each mouse was determined by measuring two dimensions with calipers and calculated using the formula: tumor volume = (length x width2). When tumors reached the average volume of approximately 75 mm3, the mice were divided into their experimental groups, which consists of untreated controls, PEG~,ooo-ala-20(S)-Camptothecin, compound 8, and compound 18.
The mice were sorted to evenly distribute tumor size, grouped into 4 to 5 mice/cage, and ear punched for permanent identification. Drugs were dosed intravenously via the tail vein as a single dose (Qdl). Mouse weight and tumor sizes were measured at the beginning of study and twice weekly through week 5.
The overall growth of tumors was calculated as the mean tumor volume at one week following the end of the treatment. A percent treatment over control (T/C) value was also calculated when the control group's median tumor size reached approximately 800-1100 mm3 and again at one week following treatment. The T/C
value in percent is a non-quantitative indication of anti-tumor effectiveness.
Treatments with PEG4o,ooo-a1a-20(S)-Camptothecin, compounds 8 and 18 all caused significantly (P<0.05) smaller tumor volumes as compared to control mice.
In addition, at equivalent doses, there was no significant (P< 0.05) difference in the antitumor activity of these three compounds.
Table 2. Efficacy Summary of PEG-Camptothecin Against a Human Mammary Carcinoma (MX-1) Xenograft in Nude Micea Compound Treatment Tumor VolumeT/C (%)a Tumor Schedule (mean t sem)At 1000 Regression mm3 at (mg/kg/dose)Day 21 Day 25 (#/grp) Control 0 2722 ~ 223 -- 0/5 PEG4o,oo0-Qdl (24) ala-20(S)- 15 t 5 1.4 5/5 Campto.
8 Qdl (24) 21 t 6 3.0 5/5 18 Qdl (24) 14 ~ 2 2.5 4/4 a, Intravenous treatment in nude mice bearing established tumors (~75 mm3).
N=4 to 5/group.
(3 The median tumor volume of treatment and control groups were measured and compared when the control group's median tumor volume reached approximately 1000 mm3 and one week after final dosage (Day 15). T/C < 42% at 1000 mm3 is considered significant anti-tumor activity by the Drug Evaluation Branch of the NCI.
While applicants are not bound by theory, it is believed that significant conversion of the open lactone E ring into the closed lactone ring has occurred in order to achieve the observed tumor regression.
The various publications, patents, patent applications and published applications mentioned in this application are hereby incorporated by reference herein in their entireties.
While there have been described what are presently believed to be the preferred embodiments of the invention, those skilled in the art will realize that changes and modifications may be made without departing from the spirit of the invention. It is intended to claim all such changes and modifications as fall within the true scope of the invention.
In one aspect of the invention, compounds of Formula (I) are provided:
(I) ;, Y~
\ ~~(Yz) a (~,) b A~
~O ~~
luu~~...
RI
OH ~~
wherein:
R~ is selected from the group consisting of amino acid residues, peptide residues containing from about 2 to about 10 amino acids, Y3-(Lz)P Az and Rz;
Y3 is O, S or NR3;
p is zero or one;
Lz is a bifunctional linker;
Y1 is O, S or NR4;
Yz is O, S, CRSR~ or NR~;
L1 is a bifunctional linker;
a and b are independently zero or one;
Ai and Az are independently selected from the group consisting of hydrogen, amino protecting groups, NRsR9, amino acid residues, peptide residues containing from about 2 to about 10 amino acids; polymeric residues, R,o, SR,1, NC(O)Riz;
D3 -D~ are independently selected from the group consisting of H, C1_g straight or branched alkyls, substituted C,_g straight or branched alkyls, aryls, substituted aryls, arylalkyls, substituted aryalkyls, C1_g alkylaryls, C1_g alkoxys, C,_s hydroxyalkyls, Ci-s aminoalkoxy, aryloxys, gycals, COZR13, R>a, nitro, cyano, halo, hydroxyl, amino, SRS, NR»R,~ or ORIg, where D4 and DS optionally, when taken together, form a saturated 3-7 membered heterocyclic ring which may contain O, S or NR,9 groups, where R,9 is hydrogen or a C1_~ alkyl;
Dg-Dlo are independently selected from the group consisting of H, C1_g straight or branched alkyls, substituted C,_g straight or branched alkyls, aryls, substituted aryls, arylalkyls, substituted aryalkyls, C1_g alkylaryls and C,_g hydroxyalkyls; and RZ_18 are independently selected from the group consisting of hydrogen, C1-s alkyls, C3-19 branched alkyls, C3-s cycloalkyls, C1-6 substituted alkyls, C3_8 substituted cyloalkyls, aryls, substituted aryls, aralkyls, C,_~
heteroalkyls, substituted C1_6 heteroalkyls, C1.6 alkoxy, phenoxy and Ci_s heteroalkoxy;
except that at least one of A, and AZ comprise a polymeric residue.
In another aspect of the invention there is provided bifunctional compounds that are formed when at least one of A1 and AZ comprises a polymeric residue and the polymeric residue is functionalized on both the alpha and omega termini to allow two equivalents of the camptothecin to be delivered per equivalent of the polymer which is preferably PEG. Such preferred compositions correspond to formulae (IIIa) and (IIIb) below:
D~
~D ~N G D V Y jn'2)a~~~)~ A' ~~
a ~ ,~ ~'z)e D
\O ~Y~ O 9 Da p~ (IIIa) Duo Vii, . CSR' G~~O N C _ ps OH\~ Rip D~ ~ B A 5.
N
OHO~\ pio ~ p , Ds °- -and .~~ O\ Da De D~
~O~N ~, B Ds O HOV,. Duo Da...
For purposes of the present invention, the term "residue" shall be understood to mean that portion of a camptothecin derivative or bifunctional spacer which remains after it has undergone a substitution reaction.
Methods of preparing the compositions of the invention and methods of treatment using the sane are also provided.
wherein all variables are as previously defined above.
For purposes of the present invention, the term "polymeric residue" or "PEG residue" shall each be understood to mean that portion of the polymer or PEG which remains after it has undergone a reaction with a heteroaromatic amine-containing compound.
For purposes of the present invention, the term "alkyl" shall be understood to include straight, branched, substituted, e.g. halo-, alkoxy-, nitro-, C1_iz alkyls, C3_g cycloalky(s or substituted cycloalkyls, etc.
For purposes of the present invention, the term "substituted" shall be understood to include adding or replacing one or more atoms contained within a functional group or compound with one or more different atoms.
For purposes of the present invention, substituted alkyls include carboxyalkyls, aminoalkyls, dialkylaminos, hydroxyalkyls and mercaptoalkyls;
substituted alkenyls include carboxyalkenyls, aminoalkenyls, dialkenylaminos, hydroxyalkenyls and mercaptoalkenyls; substituted alkynyls include carboxyalkynyls, aminoalkynyls, dialkynylaminos, hydroxyalkynyls and mercaptoalkynyls; substituted cycloalkyls include moieties such as 4-chlorocyclohexyl; aryls include moieties such as napthyl; substituted aryls include moieties such as 3-bromo-phenyl; aralkyls include moieties such as toluyl;
heteroalkyls include moieties such as ethylthiophene; substituted heteroalkyls include moieties such as 3-methoxy-thiophene; alkoxy includes moieties such as methoxy; and phenoxy includes moieties such as 3-nitrophenoxy. Halo- shall be understood to include fluoro, chloro, iodo and bromo.
The term "sufficient amounts" for purposes of the present invention shall mean an amount which achieves a therapeutic efl'ect as such effect is understood by those of ordinary skill in the art.
One advantage of the invention is that the artisan is provided with prodrugs of camptothecin derivatives with improved aqueous solubility.
Another advantage of the compounds of the invention is that in certain preferred embodiments, the releasble polymer not only extends the circulating life of the camptothecin derivative, but it also provides a means for controlling conversion of the open E-ring lactone back to the biologically active form.
This result is achieved by virtue of the fact that the open E-ring camptothecin derivative cannot hydrolyze into the closed E lactone ring until the polymer is released.
BRIEF DESCRIPTION OF THE DRAWINGS
Figures I-G schematically illustrate methods of forming compounds of the present invention which are described in the Examples.
A. FORMULA (I) In one preferred embodiment of the invention, there are provided compounds of the Formula (I):
(I) -C O
. D
~yY2) a W) ~ A~
~i III~~~~,.. C
RI
OH ~~
wherein:
Rl is selected from the group consisting of anuno acid residues, peptide residues containing from about 2 to about 10 amino acids, Y3-(LZ)p-AZ and R2;
Y3 is O, S or NR3;
p is zero or one;
L2 is a bifunctional linker;
Y~ is O, S or NRa;
Y2 is O, S, CRSR~ or NR~;
L1 is a bifunctional linker;
a and b are independently zero or one;
G
Ds Ch Do A1 and A2 are independently selected from the group consisting of hydrogen, amino protecting groups, NRgR9, amino acid residues, peptide residues containing from about 2 to about 10 amino acids; polymeric residues, RIO, SRII, NC(O)Rla;
D3 -D~ are independently selected from the group consisting of H, C1_s straight or branched alkyls, substituted CI.B straight or branched alkyls, aryls, substituted aryls, arylalkyls, substituted aryalkyls, Ci_g alkylaryls, C1_g alkoxys, CI_s hydroxyalky(s, C,_g aminoalkoxy, aryloxys, gycals, C02RI3, R14, nitro;
cyano, halo, hydroxyl, amino, SRIS, NR1~R1~ or ORIg, where D4 and DS optionally, when taken together, form a saturated 3-7 membered heterocyclic ring which may contain O, S or NR19 groups, where RIB is hydrogen or a C,_~ alkyl;
Ds-Dlo are independently selected from the group consisting of H, CI_s straight or branched alkyls, substituted C,_g straight or branched alkyls, aryls, substituted aryls, arylalkyls, substituted aryalkyls, CI_s alkylaryls and C1_8 hydroxyalkyls; and Rz_1g are independently selected from the group consisting of hydrogen, CIA alkyls, C3-19 branched alkyls, C3-g cycloalkyls, CI-~ substituted alkyls, C3_8 substituted cyloalkyls, aryls, substituted aryls, aralkyls, CI-6 heteroalkyls, substituted C1_6 heteroalkyls, CI_~ alkoxy, phenoxy and Cl_~ heteroalkoxy;
except that at least one of AI and AZ comprise a polymeric residue.
In many preferred aspects of the invention, one of A1 and AZ includes a polymer residue. The polymer residue optionally includes a capping group designated J herein. Within this aspect of the invention, when A, is a polymer residue, the capping group J is selected from among, for example, OH, NH2, SH, COzH, CI-~ alkyl moieties and Ila) DS ~~
w Alternatively, when R, is Y3-(LZ),; A2 in formula (I), and AZ is a polymer residue, the capping group J is selected from among, for example, OH, NH2, SH-, COzH, C1~ alkyl moieties and At-(Lt)b (''z) Ilb) -(LZ)-P
DS ~~
The preferred capping groups allow preferred compositions of (IIIa) and (IIIb), respectively, Ds D~ Da ~jIY2)a~Lt)b At ILI
C (~'z)fl D
O ~Yt O 9 D8 p~ (IIIa) Dto pn. C~Ri ~~O N C _ Ds off R~~ / N A 5, Dto \ v Da Da_..
and D7 ~ O Yt ~Y2ls l4,lb At yt D9 D
(IIIb) De ' ~ At-(Ltd (VZ)y ~ 8 ~ D
B C C~O~N ~.
A / D O ~~Ar-(L~-Y~ D \ B --N ~ ~ C Ys~~ ~ ° ° ~~ ~ N A DS~, D Dto ~~tnw' OH O O ~\\", Dto D4, .
to be formed, wherein all variables are as previously defined.
When LI and/or L2 include an amino acid residue, the amino acid can be selected from any of the known naturally-occurring L- amino acids is, e.g_, alanine, valine, leucine, isoleucine, glycine, serine, threonine, methionine, cysteine, phenylalanine, tyrosine, tryptophan, aspartic acid, glutamic acid, lysine, arginine, histidine, proline, and/or a combination thereof, to name but a few. When LI
and/or L2 include a peptide, the peptide ranges in size, for instance, from about 2 to about 10 amino acid residues. In one preferred embodiment, the peptide is Gly-Phe-Leu-. Alternatively, glycine can be added to the aforementioned trippeptide after leucine to form a 4 residue peptide.
The amino acid residues are preferably of the formula Ya -C-(CHZ~X' wherein X' is O, S or NR34, Y4 is 0, S or NR35, and f is a positive integer from about 1 to about 10, preferably 1; and R34 and R3s are independently selected from the same group as that which de1=tnes R3, but each is preferably H or lower alkyl.
Derivatives and analogs of the naturally occurring amino acids, as well as various art-known non-naturally occurring amino~acids (D or L), hydrophobic or non-hydrophobic, are also contemplated to be within the scope of the invention.
Simply by way of example, amino acid analogs and derivates include:
2-aminoadipic acid, 3-amino-adipic acid, beta-alanine, beta-aminopropionic acid, 2-aminobutyric acid, 4-amino-butyric acid, piperidinic acid, 6-aminocaproic acid, 2-aminoheptanoic acid,-2-aminoisobutyric acid, 3-aminoisobutyric acid, 2-aminopimelic acid, 2,4-diamino-butyric acid, desmosine, 2,2-diaminopimelic acid, 2,3-diaminopropionic acid, n-ethylglycine, N-ethylasparagine, 3-hydroxyproline, 4-hydroxyproline, isodesmo-sine, allo-isoleucine, N-methylglycine, sarcosine, N-methylisoleucine, G-N-methyl-lysine, N-methylvaline, norvaline, norleucine, ornithine, and others too numerous to mention, that are listed in 63 Fed. Reg., 29620, 29622, incorporated by reference herein.
Short peptides are, for example, peptides ranging from 2 to about 10, or more, amino acid residues, as mentioned supra.
Within most aspects of the invention, the following embodiments are preferred:
Y1 and Yz are each oxygen, RZ-R14 and D~ - Dlo are each hydrogen, L1 is selected from among (CHz)n .
(CHz)3~I-C(~) (CHz)3NH--NI-I(CH2CH20)n(CHz)n~z2-.
-NH(CH2CH20)", -NH(Cz3R24)nV-.
-C(~)(~-R2iR24)nNHC(U)((,-R25R26)q~27-, -C(0)0(CHIz)n0-, -C(O)(CR~R24)n~27-~
-C(O)NH(CH2CH20)"(CHz)nNRz7-, -C(O)O-(CH2CH20)nNRz7-~
-C(O)NH(CR23R24)n~'>
-C(~)~(CR23R24)n~-~
-C(O)NI-I(CH2CH20)", -NH(CR23R24)n ~ ' ~ (CR24R23)n0- and ~Rzs -~(CR23R24)n ~ ~ (CR24R23)~NR2~->
wherein R2z_z7 are independently selected from the group consisting of hydrogen, C1-6 alkyls, C3-12 branched alkyls, C3_s cycloalkyls, C1_~ substituted alkyls, C3_g substituted cycloalkyls, aryls substituted aryls, aralkyls, C1_~
heteroalkyls, substituted C1_~ heteroalkyls, C1_~ alkoxy, phenoxy and C1~ heteroalkoxy;
R2g is selected from the group consisting of hydrogen, C1.~ alkyls, C3_,2 branched alkyls, C3_8 cycloalkyls, C,_6 substituted alkyls, C3_g substituted cycloalkyls, aryls substituted aryls, aralkyls, C,_6 heteroalkyls, substituted C1.~ heteroalkyls, C1-~ alkoxy, phenoxy and C,_~ heteroalkoxy, NOz, haloalkyl and halogen; and n and q are independently selected positive integers.
L2 is preferably selected from among:
(CHz)j (CH2CHz0)z(CHz)zNH, -NH(CHZCH20)j(CHz)~NRz9-, -NH(CH2CH20)j-, -~(CR3oR31)j~-~
-C(~)(CR3oR31)jNHC(O)(CR3zR33)jNRz9--C(O)O(CHz~O-, -C(~)(CR30R31)jNR29-, -C(0)NH(CHzCHzO)j(CHz)kNRz9-~
-C(O)O-(CHZCH20)jNRz9-, -C(0)~(CR3oR31)j0-, -C(0)0(CR3oR3Oj0-~
-C(O)NH(CH2CH20)j-, -~(CR3oR31)j / ~ (CR3pR31)k~- and -~(CR30R31)j ~ / ~ (CR3oR3OkNR29-~
wherein Rz9_33 are independently selected from the group consisting of hydrogen, CL~ alkyls, C3_12 branched alkyls, C3_s cycloalkyls, C,_~ substituted alkyls, C3_8 substituted cycloalkyls, aryls substituted aryls, aralkyls, C1_~
heteroalkyls, substituted C1~ heteroalkyls, C1_6 alkoxy, phenoxy and C,_~ heteroalkoxy;
R34 is selected from the group consisting of hydrogen, CI_6 alkyls, C3-12 branched alkyls, C3_g cycloalkyls, C1-s substituted alkyls, C3_g substituted cycloalkyls, aryls substituted aryls, aralkyls, C1~ heteroalkyls, substituted C1~ heteroalkyls, C,_~ alkoxy, phenoxy and C1_~ heteroalkoxy, NOz, haloalkyl and halogen; and j and k are independently selected positive integers.
B. SUBSTANTIALLY NON-ANTIGENIC POLYMERS
As stated above, A1 and Az can comprise polymer residues. The polymer residues are preferably water soluble and substantially non-antigenic.
Particularly preferred polymers useful in the compositions of the present invention include polyalkylene oxides such as polyethylene glycol. The polymer residues optionally the previously mentioned capping groups, designated J, which allows a bifunctional or bis-polymer system to be formed.
In those aspects of the invention where A1 includes the polyethylene glycol residue, the PEG derivatives can be selected from the following non-limiting list:
-J-O-(CH2CH20)X , J-O-(CHZCH20)X CHZC(O)-O-, J-O-(CH~CHzO)X CHzCH2 NRZO-, J-O-(CHZCI-hO)X CH2CH2 SH-, -O-C(O)CH2-O-(CHZCHZO)X CHZC(O)-O-, -NR2oCH2CH2-O-(CH2CH20)X-CH2CH2 NRZO-, and -SHCH2CH2-O-(CH2CH20),; CH2CHz SH-, wherein:
x is the degree of polymerization;
RZO is selected from the group consisting of hydrogen, C1~ alkyls, C3_~z branched alkyls, C3_8 cycloalkyls, C1_~ substituted alkyls, C3_8 substituted cyloalkyls, aryls substituted aryls, aralkyls, C1_~ heteroalkyls, substituted Cm heteroalkyls, C~_6 alkoxy, phenoxy and C1_~ heteroalkoxy and J is a capping group.
Similarly, in those aspects of the invention where AZ includes the polyethylene glycol residue, the PEG derivatives can be selected from the following non-limiting list:
of J-0-(CHZCH20)X~ -J-O-(CH2CH20)X CH2C(O)-O-, J-O-(CH2CH20)X CH2CI-h NRz,-, J-O-(CH2CH20)x-CH2CH2 SH-, -O-C(O)CH2-O-(CH2CH20)X CH2C(O)-O-, -NR21CH2CH2-O-(CH2CH20)X CH2CH2 NRza, and -SHCH2CH2-O-(CH2CH20)x-CH2CH2 SH-, wherein:
x is the degree of polymerization;
Rz, is selected from the group consisting of hydrogen, C1-~ alkyls, C3-12 branched alkyls, C3-s cycloalkyls, C1_~ substituted alkyls, C3_s substituted cyloalkyls, aryls substituted aryls, aralkyls, C,-~ heteroalkyls, substituted C1~ heteroalkyls, C1_~ alkoxy, phenoxy and C1_~ heteroalkoxy and J is a capping group.
For the purpose of the present invention the structure:
-O-~ CH2CH20 x wherein x is a positive integer, is referred to as PEG throughout the application.
The degree of polymerization for the polymer (x) can be from about 10 to about 2,300. This represents the number of repeating units in the polymer chain and is dependent on the molecular weight of the polymer. In certain preferred aspects, the amount of polymerization is preferably sufficient to provide the polymer with a molecular weight of at least about 20,000 daltons. Since the ethylene glycol monomer has a molecular weight of 44, (x) is preferably at least about 454. The (J) moiety is a capping group as defined herein, i.e. a group which is found on the terminal of the polymer and, in some aspects, can be selected from any of NH2, OH, SH-, COZH, C1_~ alkyls or other PEG terminal activating groups, as such groups are understood by those of ordinary skill.
Also useful are polypropylene glycols, branched PEG derivatives such as those described in commonly-assigned U.S. Patent No. S,G43,575, "star-PEG's"
and multi-armed PEG's such as those described in Shearwater Corporation's 2001 catalog "Polyethylene Glycol and Derivatives for Biomedical Application". The disclosure of each of the foregoing is incorporated herein by reference. It will be understood that the water-soluble polymer can be functionalized for attachment to the bifunctional linkage groups if required without undue experimentation.
In many aspects of the present invention, bis-activated polyethylene glycols are preferred when di- or multi-substituted polymer conjugates are desired.
Alternatively, polyethylene glycols (PEG'S), mono-activated, C1-4 alkyl-terminated polyalkylene oxides (PAO's) such as mono-methyl-terminated polyethylene glycols (mPEG's) are preferred when mono-substituted polymers are desired.
In order to provide the desired hydrolyzable linkage, mono- or di-acid activated polymers such as PEG acids or PEG diacids can be used as well as mono-or di-PEG amines and mono- or di-PEG diols. Suitable PAO acids can be synthesized by first converting CH30-PEG-OH (mPEG-OH) to an ethyl ester followed by saponification. See also Gehrhardt, H., et al. Polymer Bulletin 18: 487 (1987) and Veronese, F.M., et al., J. Controlled Release 10; 145 (1989).
Alternatively, the PAO-acid can be synthesized by converting mPEG-OH into a t-butyl ester followed by acid cleavage. See, for example, commonly assigned U.S. Patent No. 5,605,976. The disclosures of each of the foregoing are incorporated by reference herein.
Although PAO's and .PEG'S can vary substantially in average molecular weight, the polymer portion of the prodrug is at least about 20,000 Da average in most aspects of the invention. Preferably, the polymer portion of the compositions has a weight average molecular weight of from about 20,000 Da to about 100,000 Da and more preferably from about 25,000 Da to about 60,000 Da. The average molecular weight of the polymer selected for inclusion in the prodrug must be sufficient so as to provide sufficient circulation of the prodrug before hydrolysis of the linker.
The polymeric substances included herein are preferably water-soluble at room temperature. A non-limiting list of such polymers include polyalkylene oxide homopolymers such as polyethylene glycol (PEG) or polypropylene glycols, polyoxyethylenated polyols, copolymers thereof and block copolymers thereof, provided that the water solubility of the block copolymers is maintained.
In a further embodiment, and as an alternative to PAO-based polymers, A1 and Az can optionally comprise one or more other effectively non-antigenic materials such as dextran, polyvinyl alcohols, carbohydrate-based polymers, hydroxypropylmeth-acrylamide (HPMA), polyalkylene oxides, and/or copolymers thereof. See also commonly-assigned U.S. Patent No, 6,153,655, the contents of which are incorporated herein by reference. It will be understood by those of ordinary skill that the same type of activation is employed as described herein as for PAO's such as PEG. Those of ordinary skill in the art will further realize that the foregoing list is merely illustrative and that all polymeric materials having the qualities described herein are contemplated. For purposes of the present invention, "effectively non-antigenic" and "substantially non-antigenic" shall be understood to include all polymeric materials understood in the art as being substantially non-toxic and not eliciting an appreciable immune response in mammals.
It will be clear from the foregoing that other polyalkylene oxide derivatives of the foregoing, such as the polypropylene glycol acids, etc., as well as other bi-functional linking groups are also contemplated.
C. CAMPTOTHECIN AND CAMPTOTHECIN ANALOGS
Camptothecin and certain related analogues and derivatives share the structure:
io;
,ti From this core structure, various derivatives are known. For example, the A
ring in either or both of the 10- and 11- positions can be substituted with an OH. The A
ring can also be substituted in the 9-position with a straight or branched C1_3o alkyl or C1_,~ alkoxy, optionally linked to the ring by a heteroatom i.e. O or S.
The B
ring can be substituted in the 7-position with a straight or branched C~_3o alkyl or substituted alkyl-, Cs_s cycloalkyl, C~_3o alkoxy, phenyl alkyl, etc., alkyl carbamate, alkyl carbazides, phenyl hydrazine derivatives, amino, aminoalkyl, aralkyl, etc.
Other substitutions are possible in the C, D and E rings. See, for example, U.S. Pat.
Nos. 5,004,758, 4,943,579, Re 32,518, 4,894,456, 5,225, 5,053,512, 4,981,968, 5,049,668, 5,106,742, 5,180,722, 5,244,903, 5,227,380, 5,122,606, 5,122,526, and 5,340,817, the contents of each of which are incorporated herein by reference.
In most aspects of the invention, the camptothecin derivatives which are employed in the formation of the compositions of the present invention are generally of the formula m E
luu~~,.. C
OH ~~
wherein:
D3 -D~ are independently selected from the group consisting of H, C,_8 straight or branched alkyls, substituted C,_g straight or branched alkyls, aryls, substituted aryls, arylalkyls, substituted aryalkyls, C,-g alkylaryls, C1_g alkoxys, C,-s hydroxyalkyls, C,_s aminoalkoxy, aryloxys, gycals, COzR,3, R14, vitro, cyano, halo, hydroxyl, amino, SR,S, NR1~R,~ or OR,g, where D4 and DS optionally, when taken together, form a saturated 3-7 membered heterocyclic ring which may contain O, S or NR,9 groups, where R,9 is hydrogen or a C,_6 alkyl;
Dg-D,o are independently selected from the group consisting of H, C,-g straight or branched alkyls, substituted C,_s straight or branched alkyls, aryls, substituted aryls, arylalkyls, substituted aryalkyls, C,-s alkylaryls and C,_s hydroxyalkyls; and Rg_,g are independently selected from the group consisting of hydrogen, C1_6 alkyls, C3_,9 branched alkyls, C3_8 cycloalkyls, C,_~ substituted alkyls, C3_s substituted cyloalkyls, aryls, substituted aryls, aralkyls, C,~
heteroalkyls>
substituted C,.s heteroalkyls, C,-6 alkoxy, phenoxy and C,_6 heteroalkoxy.
In other preferred aspects of the invention, the following can be used:
irinotecan H
iopotecan Still further camptothecin analogs which can be used in the practice of the present invention include, 10,11-oxycamptothecin, 10,11-methylene dioxycamptothecin, 7-ethylcamptothecin, 9-amino-camptothecin, to name but a few.
Those of ordinary skill will realize that the foregoing is merely illustrative of the camptothecin derivatives useful in practicing the present invention.
The only limitations on the camptothecin derivatives useful in the invention is that the specific derivative must be capable of undergoing the opening of the E-lactone ring, allowing a polymer to be attached thereto and, after administration, allowing hydrolysis to occur which allows the E-lactone ring to be re-formed in vivo.
D. SYNTHESIS OF THE CAMPTOTHECIN-POLYMERIC
PRODRUGS
Synthesis of specific representative polymer prodrugs is set forth in the Examples. Generally, however, in one preferred method of preparing the prodrug transport systems of the present invention, the E-lactone ring is opened, a capped bifunctional linker is attached at the 17-position of the open lactone ring, the blocking group is removed and followed by PEGylation with appropriate solvent and coupling agent, if required. The lactone ring can be opened using known techniques such as by dissolving the camptothecin derivative in N,N
dimethylethylenediamine (2 in the examples) or in isopropylamine (9 in the examples) or other suitable reagent solvents containing a primary amine and heating the reaction solution for a sufficient amount of time to allow the ring to be opened.
Once the E ring has been opened, the artisan is provided with a camptothecin derivative of the formula:
(t~) \OH
11~~~~"..
OH ~~
wherein:
Rl is selected from the group consisting of amino acid residues, peptide residues containing from about 2 to about 10 amino acids, Y3-(Lz)n AZ and R2;
Y3 is O, S or NR3;
p is zero or one;
L2 is a bifunctional linker;
A2 is selected from the group consisting of hydrogen, amino protecting groups, NRaR9, amino acid residues, peptide residues containing from about 2 to about amino acids; polymeric residues, Rlo, SCRII, NC(O)R12;
D3-D~ are independently selected from the group consisting of H, C1_s straight or branched alkyls, substituted C1_8 straight or branched alkyls, aryls, substituted aryls, arylalkyls, substituted aryalkyls, C1_s alkylaryls, C~_g alkoxys, C~_8 hydroxyalkyls, Ci-s aminoalkoxy, aryloxys, gycals, COzR,3, R14, vitro, cyano, halo, hydroxyl, amino, SR,S, NR,~RI~ or OR,g, where D4 and DS optionally, when taken together, form a saturated 3-7 membered heterocyclic ring which may contain O, S or NR~9 groups, where R19 is hydrogen or a C~_6 alkyl;
Ds-Duo are independently selected from the group consisting of H, C1_8 straight or branched alkyls, substituted C,_s straight or branched alkyls, aryls, substituted aryls, arylalkyls, substituted aryalkyls, C1_g alkylaryls and C1_g hydroxyalkyls; and R2_,g are independently selected from the group consisting of hydrogen, C1~ alkyls, C3-19 branched alkyls, Cs_s cycloalkyls, C1_~ substituted alkyls, C3_8 substituted cyloalkyls, aryls, substituted aryls, aralkyls, C,_~
heteroalkyls, substituted C» heteroalkyls, C1-6 alkoxy, phenoxy and C~_s heteroalkoxy;
which is then reacted with a blocked bifunctional spacer to form a protected intermediate. This intermediate is then deblocked and reacted with an activated polymer under conditions sufT'icient to cause a polymeric conjugate to be formed.
A non-limiting list of activated polymers include bis-succinimidyl carbonate activated PEG (SC-PEG), bis-thiazolidine-2-thione activated PEG (T-PEG), N-hydroxyphthalamidyl carbonate activated PEG (BSC-PEG), see commonly assigned USSN 09/823,296, the disclosure of which is incorporated herein by reference, succinimidyl succinate activated PEG (SS-PEG), imidazole-activated PEG (PEG-IMD), bis-carboxylic acid- PEG (PEG-COZH) and mono-activated PEG's such as those found in, for example, in the aforementioned Shearwater Catalog.
Conjugation of the intermediate to the PEG residue can be carried out in the presence of a coupling agent. A non-limiting list of suitable coupling agents include 1,3-diisopropylcarbodiimide (DIPC), any suitable dialkyl carbodiimide, 2-halo-1-alkyl-pyridinium.halides (Mukaiyama reagents), 1-(3-dimethylamino-propyl)-3-ethyl carbodiimide (EDC), propane phosphonic acid cyclic anhydride (PPACA) and phenyl dichlorophosphates, etc. which are available, for example from commercial sources such as Sigma-Aldrich Chemical, or synthesized using known techniques.
Preferably the substituents are reacted in an inert solvent such as tetrahydrofuran (THF), acetonitrile (CH3CN), methylene chloride (DCM), chloroform (CHC13), dimethylformamide (DMF) or mixtures thereof. The reaction is preferably conducted in the presence of a base, such as dimethylaminopyridine (DMAP), diisopropyl ethylamine, pyridine, triethylamine, KOH, potassium t-butoxide and NaOH, etc. and at a temperature from 0° C up to about 22° C (room temperature).
In an alternative embodiment, the compositions of the present invention are prepared by using the blocked bifunctional spacer to open the E-lactone ring in an inert solvent, acylating the 17-position OH group with, for example acetic or butyric anhydride, debloching the bifunctional spacer and attaching the polymer.
Specifically, the reaction involves reacting a compound of the formula -C O
(V) .. Da uu""..
OH ~~
wherein:
D3 -D~ are independently selected from the group consisting of H, C1_8 straight or branched alkyls, substituted C1_g straight or branched alkyls, aryls, substituted aryls, arylalkyls, substituted aryalkyls, C,_s alkylaryls, C,_s alkoxys, C,_8 hydroxyalkyls, C1_g aminoalkoxy, aryloxys, gycals, C02R~3, R,4, nitro, cyano, halo, hydroxyl, amino, SR,S, NR,~R» or OR,B, where D4 and DS optionally, when taken together, form a saturated 3-7 membered heterocyclic ring which may contain O, S or NR,9 groups, where R,~ is hydrogen or a C1_6 alkyl;
D8-Dlo are independently selected from the group consisting of H, C1_8 straight or branched alkyls, substituted C~_s straight or branched alkyls, aryls, substituted aryls, arylalkyls, substituted aryalkyls, C1_g alkylaryls and C1_g hydroxyalkyls; and Rg_I8 are independently selected from the group consisting of hydrogen, CI_~ alkyls, C3_19 branched alkyls, C3_g cycloalkyls, CI_~ substituted alkyls, C3_ssubstituted cyloalkyls, aryls, substituted aryls, aralkyls, CL~
heteroalkyls, substituted C1~ heteroalkyls, CI-6 alkoxy, phenoxy and CI_6 heteroalkoxy;
with a blocked bifunctional spacer in an inert solvent under conditions sufficient to open the E lactone and form a blocked intermediate of formula (VI) ~C
._Da Rss wherein R35 is a residue of a blocked bifunctional spacer;
b) acylating the CIA hydroxyl of the blocked intermediate, and c) deprotecting the blocked intermediate and reacting it with an activated polymer under conditions sufficient to cause a polymeric conjugate to be formed.
Regardless of the synthesis selected, some of the preferred compounds which result from the synthetic techniques described herein include:
,..o:
~2)a(L~)b A' (L~~ (~'2)e D
O 9 D8 ~ (IIIa) .O N C _ Ds D B
R~~ ~ N A 5.
Duo , D3 ~4_.
and pg Y~ ~~4~1e A~
(IIIb) D6 D7 p ~~(Y2~, A~_(L~~ (v~\~~ p D9 pe D~
C N ~ w N pe 8 p ~ p p C
C Y3~~~zlpAYI~~Y~C ~ N~DS,, N ~ ~_ '~_D~
Da .
Dz D pH p p Hp p ~ _.
where all variables are as previously defined and O
O p NH-~--PEG
N N O-~ ~/
O
O
HO
NH~NMey , O
~O~NH~PEG
\'O
Y
O O
N \ / O-ll-CH3 HO O O
N~O~O~NH~--PEG
H
j N_ O O~~O~NH-~L--O-~CHZ-CHz-O-~-II-N~p O N i i N ~ / O O _ \ / wN~~
O
HO .. ...OH and NH' / ~NH
where PEG = Me-0-(CHZCHzO)X or -O-(CHzCH20)X .
H H
E. METHODS OF TREATMENT
Another aspect of the present invention provides methods of treatment for various medical conditions, including topoisomerase inhibitor-related diseases in mammals. The methods include administering to the mammal in need of such treatment, an effective amount of a prodrug, of a camptothecin, camptothecin derivative, camptothecin analog and/or a mixture thereof, such as,those described herein. The compositions are useful for, among other things, treating neoplastic disease, reducing tumor burden, preventing metastasis of neoplasms and preventing recurrences of tumor/neoplastic growths in mammals.
The amount of the inventive composition administered will depend upon several factors, including potency of the parent molecule included therein and specific disease being treated. Generally, the amount of prodrug used in the treatment methods is that amount which effectively achieves the desired therapeutic result in mammals. Naturally, the dosages of the various prodrug compounds will vary somewhat depending upon the parent compound, rate of in vivo hydrolysis of the open E ring, the molecular weight of the polymer used, if any, etc. In general, dosing is based upon the amount of native (unmodified E-lactone ring) camptothecin or derivative thereof The camptothecin and derivatives of camptothecin are generally administered in amounts ranging from about 5 to about 500 mg/m2 per day. The range set forth above is illustrative and those skilled in the art will determine the optimal dosing of the prodrug selected based on clinical experience and the treatment indication.
The compositions, including prodrugs, of the present invention can be included in one or more suitable pharmaceutical compositions for administration to mammals. The pharmaceutical compositions may be in the form of a solution, suspension, tablet, capsule or the like, prepared according to methods well known in the art. It is also contemplated that administration of such compositions may be by the oral, inhalation and/or parenteral routes depending upon the needs of the artisan. A solution and/or suspension of the composition may be utilized, for example, as a carrier vehicle for injection or infiltration of the composition by any art la~own methods, e.g., by intravenous, intramuscular, subdermal injection and the like. Such administration may also be by infusion into a body space or cavity, as well as by inhalation and/or intranasal routes. 1n preferred aspects of the invention, however, the prodrugs are parenterally administered to mammals in need thereof.
EXAMPLES
The following examples serve to provide further appreciation of the invention but are not meant in any way to restrict the effective scope of the invention. All compounds mentioned in the following examples are numbered with reference to Figs 1-6.
General Procedures. All reactions were run under an atmosphere of dry nitrogen or argon. Commercial reagents were used without further purification. All PEG
compounds were 40kDa and were dried under vacuum or by azeotropic distillation from toluene prior to use. '3C NMR spectra were obtained at 75.46 MHz using a Varian Mercury 300 NMR spectrometer and deuterated chloroform as the solvent unless otherwise specified. Chemical shifts (8) are reported in parts per million (ppm) downfield from tetramethylsilane (TMS). All PEG conjugated compounds were dissolved in saline for injection prior to in vivo drug treatments and were given as their camptothecin equivalents (absolute amount of camptothecin given).
HPLC method. The reaction mixtures and the purity of intermediates and final products were monitored by a Beckman Coulter System Gold' HPLC instrument employing a ZOBAX'~ 300 SB C-8 reversed phase column (I50 x 4.6 mm) or a Phenomenex Jupiter 300A C18 reversed phase column (150 x 4.6 mm) with a multiwavelength UV detector, using a gradient of 30-90 % of acetonitrile in 0.5 trifluoroacetic acid (TFA) at a flow rate of 1 mL/min.
Example 1 Compound 5. Camptothecin (1) (1.44 g, 4.14 mmol) was dissolved in N,N-dimethylethylenediamine (2) (IS mL) and the reaction solution was heated at 50 °C for 2 hours. The solvent was removed under reduced pressure and the resulting solid washed with ether to give 3, which was suspended with dimethylamino-pyridine (DMAP, 1.0 g, 8.88 mmol) and 4 (1.3 g, 4.44 mmol) in anhydrous methylene chloride (DCM, 10 mL). The resulting reaction mixture was refluxed for 4 hours and then stirred at room temperature for 12 hours, washed with O.1N
HCI, dried with MgS04, filtered, and solvent evaporated under reduced pressure.
The crude material was purif ed on silica gel column to give 5 (0.080 g, 0.13 mmol, 3 %). '3C NMR (67.8 MHz, CDCI~) b 167.26, 157.15, 155.77, 153.69, 152.18, 148.76, 146.33, 145.71, 131.14, 130.65, 129.56, 128.37, 128.10, 128.02, 120.10, 95.82, 79.14, 77.83, 77.20, 67.01, GG.50, 50.03, 36.97, 31.84, 29.01, 28.37, 25.59, 7.73.
Example 2 Compound G. To a solution of 5 (0.080 g, 0.13 mmol) in DCM (1 mL) cooled in an ice bath, trifluoroacetic acid (TFA, 1 mL) was added drop-wise and stirred for min. 'The solvents were then removed under reduced pressure to give 6 (0.080 g, 0.13 mmol, 100 %). '3C NMR (67.8 MHz, CDC13) 8 167.50, 157.01, 153.95, 146.42, 145.31, 143.81, 134.69, 132.80, 129.26, 129.08, 128.52, 126.56, 120.92, 15 98.92, 78.27, 77.21, G6.G9, 65.27, 50.47, 37.15, 31.33, 26.55, 25.58, 7.53.
Example 3a Compound 8~. A solution of G (0.080 g, 0.13 mmol), 7a (1.50 g, 0.037 mmol), and DMAP (0.031 g, 0.25 mmol) in DCM (8 mL) was stirred at room temperature for 12 hours. The reaction mixture was washed with O.1N HCI (2x10 mL) and the 20 organic layer evaporated under reduced pressure. The solid residue was crystallized from isopropyl alcohol (IPA, 30 mL) to yield 8a (1.2 g, 0.029 mmol, 79 %). '3C NMR (67.8 MHz, CDCI3) 8 166.41, 156.36, 155.64, 152.92, 151.50, 148.01, 145.76, 144.89, 130.76, 129.90, 128.84, 127.95, 127.58, 127.29, 119.31, 94.90, 67.0-73.5 (PEG), 66.29, 65.78, 63.05, 49.46, 36.69, 31.12, 28.39, 7.14.
Example 3b Compound 8b. The procedure of Example 3~ is followed, except that PEG-C02H
7b (1.5 g, 0.037 mmol) and 2 equivalents of EDC is used in place of 7a to form an amide-linked PEG conjugate.
Example 4 Compound 11. 1 (1.44g, 4.14 mmol) was dissolved in isopropylamine 9 (35m1) and the solution refluxed for 1.5 hours. The solvent was removed under reduced pressure and the resulting solid washed with ether to give 10, which was suspended with DMAP (0.29 g, 2.36 mmol) and 4 (0.36 g, 1.18 mmol) in anhydrous chloroform (2 mL). The resulting reaction mixture was heated at 60 °C
for 1 hour, washed with O.1N HCI, dried (MgS04), filtered, and the solvent evaporated under reduced pressure. The crude material was purif ed by column chromatography to give 11 (0.068 g, 0.11 mmol, 3 %). '3C NMR (67.8 MHz, CDC13) 8 171.26, 161.43, 156.41, 155.92, 155.33, 152.09, 148.46, 144.57, 130.66, 130.22, 129.37, 128.37, 127.90, 127.71, 123.90, 100.57, 79.17, 77.20, 75.92, 65.22, 62.13, 50.27, 41.72, 37.09, 32.87, 29.33, 28.46, 22.74, 22.44, 7.90.
Example 5 Compound 12. To a solution of compound 11 (0. 68 g, 0.11 mmol) in DCM (1 mL), cooled in an ice bath, was added TFA (1 mL) drop-wise and the solution stirred for 2 hours. The solvents were removed under reduced pressure to give (0.067 g, 0.11 mmol, 100 %). '3C NMR (67.8 MHz, CDCl3/CD30D) b 171.74, 161.75, 157.19, 154.76, 152.01,.148.27, 144.55, 131.41, 130.62, 128.90, 128.58, 128.08, 127.91, 123.53, 101.24, 78.50, 64.99, 62.33, 50.23, 41.55, 37.06, 32.19, 26.35, 22.32, 22.00, 7.55.
Example 6a Compound 13a. A solution of 12 (0.067 g, 0.11 mmol), 7a, (1.30 g, 0.032 mmol), and DMAP (0.027 g, 0.22 mmol) in DCM (8 mL) was stirred at room temperature for 12 hours. The reaction mixture was washed with O.1N HC1 (2x10 mL) and the organic layer evaporated under reduced pressure. The solid residue was crystallized from IPA (30 mL) to yield 13a (1.1 g, 0.028 mmol, 86 %). '3C NMR
(67.8 MHz, CDCl3) 8 170.64, 160.74, 155.82, 154.54, 151.65, 147.90, 144.02, 134.37, 130.35, 129.57, 128.77, 128.03, 127.43, 127.20, 99.61, 67.0-73.5 (PEG), 64.63, 63.23, 61.49, 49.71, 41.07, 37.02, 32.11, 28.74, 22.20, 21.84, 7.41.
Example Gb Compound 13b. The procedure of Example 6a is followed, except that PEG-COzH
7b (1.5 g, 0.037 mmol) is used with 2 equivalents of EDC in place of 7a to form an amide-linked PEG conjugate.
Example 7 Compound 16. A mixture of 1 (0.34 g, 0.97 mmol), 14 (4.7 g, 19 mmol), and diisopropylethylamine (DIEA, 3.3 mL, 1.4 mmol) in dimethylformamide (DMF, 7 mL) was heated at 70 °C for 48 hours and a clear solution was obtained.
The solvent was removed under reduced pressure, and the resulting solid washed with hexane and then ether to give 15 which was suspended in anhydrous DCM (10 mL) and cooled to 0 °C in an ice bath. Acetic anhydride (0.10 mL, 1.1 mmol) and DMAP (0.057 g, 0.47 mmol) were added to the above suspension and stirred for 3 hours at ambient temperature. The reaction mixture was washed with 0.1 N
sodium bicarbonate (10 mL), and the organic layer evaporated under reduced pressure. The residue was purif ed on silica gel column to give pure 16 (0.25 g, 0.39 mmol, 40 %). ~3C NMR (67.8 MHz, CDCl3) 8 172.19, 170.95, 161.38, 156.80, 155.91, 151.42, 148.04, 144.05, 130.42, 130.00, 128.92, 127.89, 127.68, 127.58, 127.26, 124.77, 100.60, 79.15, 78.55, 70.14, 69.37, 58.78, 50.23, 40.33, 39.04, 32.93, 28.40, 20.99, 7.92.
Example 8 Compound 17. To a solution of 1G (0.12 g, 0.19 mmol) in DCM (1 mL) cooled in an ice bath was added TFA (1 mL) dropwise and stirred for 30 minutes. Solvent was removed under reduced pressure to give 6 (0.12 g, 0.19 mmol, 100 %). '3C
NMR (67.8 MHz, CDC13) 8 173.01, 172.22, 161.33, 157.08, 149.97, 146.13, 142.92, 132.94, 131.47, 128.55, 128.40, 128.10, 127.67, 127.23, 125.13, 117.41, 113.59, 102.62, 78.65, 70.19, 69.37, 66.48, 58.63, 50.67, 40.06, 39.28, 32.68, 20.78, 7.62.
Example 9a Compound 18a. A solution of 17 (0.050 g, 0.090 mmol), 7a (1.20 g, 0.030 mmol), and DMAP (0.022 g, 0.18 mmol) in DCM (G mL) was stirred at room temperature for 12 hours. The reaction mixture was washed with 0.1N HCI (2x10 mL) and the organic layer evaporated under reduced pressure. The solid residue was crystallized from IPA (30 mL) to yield 18a (1.1 g, 0.027 mmol, 89 %). '3C NMR
(67.8 MHz, CDC13) 8 171.82, 170.32, 160.71, 155.75, 155.23, 151.59, 147.82, 143.79, 134.41, 130.30, 129.55, 128.70, 127.90, 127.42, 127.11, 124.07, 99.59, 67.0-73.5 (PEG), 63.14, 58.50, 49.61, 40.17, 38.58, 32.14, 20.48, 7.38.
Example 9b Compound 186. The procedure of Example 9a is followed, except that PEG-COZH 7b (1.5 g, 0.037 mmol) is used with 2 equivalents of EDC in place of 7a to form an amide-linked PEG conjugate.
Example 10 The efficacy of open-form ca~nptothecin analogs against a subcutaneous human mammary carcinoma (MX-1) grown in nude mice was determined as follows.
Following at least one week of acclimation, tumors were established by implanting small tumor fragments from donor mice into a single subcutaneous site, on the left axillary flank region of nude mice. The tumor implantation site was observed twice weekly and measured once palpable. The tumor volume for each mouse was determined by measuring two dimensions with calipers and calculated using the formula: tumor volume = (length x width2). When tumors reached the average volume of approximately 75 mm3, the mice were divided into their experimental groups, which consists of untreated controls, PEG~,ooo-ala-20(S)-Camptothecin, compound 8, and compound 18.
The mice were sorted to evenly distribute tumor size, grouped into 4 to 5 mice/cage, and ear punched for permanent identification. Drugs were dosed intravenously via the tail vein as a single dose (Qdl). Mouse weight and tumor sizes were measured at the beginning of study and twice weekly through week 5.
The overall growth of tumors was calculated as the mean tumor volume at one week following the end of the treatment. A percent treatment over control (T/C) value was also calculated when the control group's median tumor size reached approximately 800-1100 mm3 and again at one week following treatment. The T/C
value in percent is a non-quantitative indication of anti-tumor effectiveness.
Treatments with PEG4o,ooo-a1a-20(S)-Camptothecin, compounds 8 and 18 all caused significantly (P<0.05) smaller tumor volumes as compared to control mice.
In addition, at equivalent doses, there was no significant (P< 0.05) difference in the antitumor activity of these three compounds.
Table 2. Efficacy Summary of PEG-Camptothecin Against a Human Mammary Carcinoma (MX-1) Xenograft in Nude Micea Compound Treatment Tumor VolumeT/C (%)a Tumor Schedule (mean t sem)At 1000 Regression mm3 at (mg/kg/dose)Day 21 Day 25 (#/grp) Control 0 2722 ~ 223 -- 0/5 PEG4o,oo0-Qdl (24) ala-20(S)- 15 t 5 1.4 5/5 Campto.
8 Qdl (24) 21 t 6 3.0 5/5 18 Qdl (24) 14 ~ 2 2.5 4/4 a, Intravenous treatment in nude mice bearing established tumors (~75 mm3).
N=4 to 5/group.
(3 The median tumor volume of treatment and control groups were measured and compared when the control group's median tumor volume reached approximately 1000 mm3 and one week after final dosage (Day 15). T/C < 42% at 1000 mm3 is considered significant anti-tumor activity by the Drug Evaluation Branch of the NCI.
While applicants are not bound by theory, it is believed that significant conversion of the open lactone E ring into the closed lactone ring has occurred in order to achieve the observed tumor regression.
The various publications, patents, patent applications and published applications mentioned in this application are hereby incorporated by reference herein in their entireties.
While there have been described what are presently believed to be the preferred embodiments of the invention, those skilled in the art will realize that changes and modifications may be made without departing from the spirit of the invention. It is intended to claim all such changes and modifications as fall within the true scope of the invention.
Claims (30)
1. A compound comprising Formula I:
wherein:
R1 is selected from the group consisting of amino acid residues, peptide residues containing from about 2 to about 10 amino acids, Y3-(L2)p-A2 and R2;
Y3 is O, S or NR3;
p is zero or one;
L2 is a bifunctional linker;
Y1 is O, S or NR4;
Y2 is O, S, CR5R6 or NR7;
L1 is a bifunctional linker;
a and b are independently zero or one;
A1 and A2 are independently selected from the group consisting of hydrogen, amino protecting groups, NR8R9, amino acid residues, peptide residues containing from about 2 to about 10 amino acids; polymeric residues, R10, SR11, NC(O)R12;
D3-D7 are independently selected from the group consisting of H, C1-8 straight or branched alkyls, substituted C1-8 straight or branched alkyls, aryls, substituted aryls, arylalkyls, substituted aryalkyls, C1-8 alkylaryls, C1-8 alkoxys, C1-8 hydroxyalkyls, C1-8 aminoalkoxy, aryloxys, gycals, CO2R13, R14, nitro, cyano, halo, hydroxyl, amino, SR15, NR16R17 or OR18, where D4 and D5 optionally, when taken together, form a saturated 3-7 membered heterocyclic ring which may contain O, S or NR19 groups, where R19 is hydrogen or a C1-6 alkyl;
D8-D10 are independently selected from the group consisting of H, C1-8 straight or branched alkyls, substituted C1-8 straight or branched alkyls, aryls, substituted aryls, arylalkyls, substituted aryalkyls, C1-8 alkyl aryls and C1-8 hydroxyalkyls; and R2-18 are independently selected from the group consisting of hydrogen, C1-6 alkyls, C3-19 branched alkyls, C3-8 cycloalkyls, C1-6 substituted alkyls, C3-8 substituted cyloalkyls, aryls, substituted aryls, aralkyls, C1-6 heteroalkyls, substituted C1-6 heteroalkyls, C1-6 alkoxy, phenoxy and C1-6 heteroalkoxy;
provided that at least one of A1 and A2 comprise a polymeric residue.
wherein:
R1 is selected from the group consisting of amino acid residues, peptide residues containing from about 2 to about 10 amino acids, Y3-(L2)p-A2 and R2;
Y3 is O, S or NR3;
p is zero or one;
L2 is a bifunctional linker;
Y1 is O, S or NR4;
Y2 is O, S, CR5R6 or NR7;
L1 is a bifunctional linker;
a and b are independently zero or one;
A1 and A2 are independently selected from the group consisting of hydrogen, amino protecting groups, NR8R9, amino acid residues, peptide residues containing from about 2 to about 10 amino acids; polymeric residues, R10, SR11, NC(O)R12;
D3-D7 are independently selected from the group consisting of H, C1-8 straight or branched alkyls, substituted C1-8 straight or branched alkyls, aryls, substituted aryls, arylalkyls, substituted aryalkyls, C1-8 alkylaryls, C1-8 alkoxys, C1-8 hydroxyalkyls, C1-8 aminoalkoxy, aryloxys, gycals, CO2R13, R14, nitro, cyano, halo, hydroxyl, amino, SR15, NR16R17 or OR18, where D4 and D5 optionally, when taken together, form a saturated 3-7 membered heterocyclic ring which may contain O, S or NR19 groups, where R19 is hydrogen or a C1-6 alkyl;
D8-D10 are independently selected from the group consisting of H, C1-8 straight or branched alkyls, substituted C1-8 straight or branched alkyls, aryls, substituted aryls, arylalkyls, substituted aryalkyls, C1-8 alkyl aryls and C1-8 hydroxyalkyls; and R2-18 are independently selected from the group consisting of hydrogen, C1-6 alkyls, C3-19 branched alkyls, C3-8 cycloalkyls, C1-6 substituted alkyls, C3-8 substituted cyloalkyls, aryls, substituted aryls, aralkyls, C1-6 heteroalkyls, substituted C1-6 heteroalkyls, C1-6 alkoxy, phenoxy and C1-6 heteroalkoxy;
provided that at least one of A1 and A2 comprise a polymeric residue.
2. The compound of claim 1, wherein Y1 and Y2 are each O.
3. The compound of claim 1, wherein R2-R14 and D3-D10 are each hydrogen.
4. The compound of claim 1, wherein A, is a polymer residue.
5. The compound of claim 4, wherein said polymer residue further includes a capping group J, selected from the group consisting of OH, NH2, SH, CO2H, C1-6 alkyl moieties and
6. A compound of claim 5, of the formula:
7. The compound of claim 1, wherein A2 is a polymer residue.
8. The compound of claim 7, wherein said polymer residue further includes a capping group J, selected from the group consisting of OH, NH2, SH, CO2H, C1-6 alkyl moieties and
9. A compound of claim 8, of the formula:
10. The compound of claim 1, wherein A1 comprises a polyalkylene oxide residue.
11. The compound of claim 1, wherein A2 comprises a polyalkylene oxide residue.
12. The compound of claim 1, wherein A1 comprises a polyethylene glycol residue.
13. The compound of claim 1, wherein A2 comprises a polyethylene glycol residue.
14. The compound of claim 6, wherein A1 comprises a polyethylene glycol residue.
15. The compound of claim 9, wherein A2 comprises a polyethylene glycol residue.
16. The compound of claim 12, wherein A1 is selected from the group consisting of J-O-(CH2CH2O)x-, J-O-(CH2CH2O)x-CH2C(O)-O-, J-O-(CH2CH2O)x-CH2CH2-NR20-, J-O-(CH2CH2O)x-CH2CH2 SH-, -O-C(O)CH2-O-(CH2CH2O)x-CH2C(O)-O-, -NR20CH2CH2-O-(CH2CH2O)x-CH2CH2 NR20-, and -SHCH2CH2-O-(CH2CH2O)x-CH2CH2 SH-, wherein:
x is the degree of polymerization;
R20 is selected from the group consisting of hydrogen, C1-6 alkyls, C3-12 branched alkyls, C3-8 cycloalkyls, C1-6 substituted alkyls, C3-8 substituted cyloalkyls, aryls substituted aryls, aralkyls, C1-6 heteroalkyls, substituted C1-6 heteroalkyls, C1-6 alkoxy, phenoxy and C1-6 heteroalkoxy and J is a capping group.
x is the degree of polymerization;
R20 is selected from the group consisting of hydrogen, C1-6 alkyls, C3-12 branched alkyls, C3-8 cycloalkyls, C1-6 substituted alkyls, C3-8 substituted cyloalkyls, aryls substituted aryls, aralkyls, C1-6 heteroalkyls, substituted C1-6 heteroalkyls, C1-6 alkoxy, phenoxy and C1-6 heteroalkoxy and J is a capping group.
17. The compound of claim 13, wherein A2 is selected from the group consisting of J-O-(CH2CH2O)x, -J-O-(CH2CH2O)x-CH2C(O)-O-, J-O-(CH2CH2O)x-CH2CH2 NR21-, J-O-(CH2CH2O)x-CH2CH2 SH-, -O-C(O)CH2-O-(CH2CH2O)x-CH2C(O)-O-, -NR2ICH2CH2-O-(CH2CH2O)x-CH2CH2 NR21, and -SHCH2CH2-O-(CH2CH2O)x-CH2CH2 SH-, wherein:
x is the degree of polymerization;
R2, is selected from the group consisting of hydrogen, C1-6 alkyls, C3-12 branched alkyls, C3-8 cycloalkyls, C1-6 substituted alkyls, C3-8 substituted cyloalkyls, aryls substituted aryls, aralkyls, C1-6 heteroalkyls, substituted C1-6 heteroalkyls, C1-6 alkoxy, phenoxy and C1-6 heteroalkoxy and J is a capping group.
x is the degree of polymerization;
R2, is selected from the group consisting of hydrogen, C1-6 alkyls, C3-12 branched alkyls, C3-8 cycloalkyls, C1-6 substituted alkyls, C3-8 substituted cyloalkyls, aryls substituted aryls, aralkyls, C1-6 heteroalkyls, substituted C1-6 heteroalkyls, C1-6 alkoxy, phenoxy and C1-6 heteroalkoxy and J is a capping group.
18. The compound of claim 16, wherein A1 comprises -O-(CH2CH2O)x- and x is a positive integer selected so that the weight average molecular weight is at least about 20,000 Da.
19. The compound of claim 17, wherein A2 comprises -O-(CH2CH2O)x- and x is a positive integer selected so that the weight average molecular weight thereof is at least about 20,000 Da.
20. The compound of claim 16, wherein A1 has a weight average molecular weight of from about 20,000 Da to about 100,000 Da.
21. The compound of claim 17, wherein A2 has a weight average molecular weight of from about 20,000 Da to about 100,000 Da.
22. The compound of claim 16G, wherein A1 has a weight average molecular weight of from about 25,000 Da to about 60,000 Da.
23. The compound of claim 17, wherein A2 has a weight average molecular weight of from about 25,000 Da to about 60,000 Da.
24. The compound of claim 1, wherein L1 is selected from the group consisting of:
(CH2)n, (CH2)3NH-C(O) (CH2)3NH--NH(CH2CH2O)n(CH2)n NR22-, -NH(CH2CH2O)n-, -NH(C23R24)n O-, -C(O)(CR23R24)n NHC(O)(CR25R26)q NR27-, -C(O)O(CH2)n O-, -C(O)(CR23R24)n NR27-, -C(O)NH(CH2CH2O)n(CH2)n NR27-, -C(O)O-(CH2CH2O)n NR27-, -C(O)NH(CR23R24)n O-, -C(O)O(CR23R24)n O-, -C(O)NH(CH2CH2O)n-, wherein R22-27 are independently selected from the group consisting of hydrogen, C1-6 alkyls, C3-12 branched alkyls, C3-8 cycloalkyls, C1-6 substituted alkyls, C3-8 substituted cycloalkyls, aryls substituted aryls, aralkyls, C1-6 heteroalkyls, substituted C1-6 heteroalkyls, C1-6 alkoxy, phenoxy and C1-6 heteroalkoxy;
R28 is selected from the group consisting of hydrogen, C1-6 alkyls, C3-12 branched alkyls, C3-8 cycloalkyls, C1-6 substituted alkyls, C3-8 substituted cycloalkyls, aryls substituted aryls, aralkyls, C1-6 heteroalkyls, substituted C1-6 heteroalkyls, C1-6 alkoxy, phenoxy and C1-6 heteroalkoxy, NO2, haloalkyl and halogen; and n and q are independently selected positive integers.
(CH2)n, (CH2)3NH-C(O) (CH2)3NH--NH(CH2CH2O)n(CH2)n NR22-, -NH(CH2CH2O)n-, -NH(C23R24)n O-, -C(O)(CR23R24)n NHC(O)(CR25R26)q NR27-, -C(O)O(CH2)n O-, -C(O)(CR23R24)n NR27-, -C(O)NH(CH2CH2O)n(CH2)n NR27-, -C(O)O-(CH2CH2O)n NR27-, -C(O)NH(CR23R24)n O-, -C(O)O(CR23R24)n O-, -C(O)NH(CH2CH2O)n-, wherein R22-27 are independently selected from the group consisting of hydrogen, C1-6 alkyls, C3-12 branched alkyls, C3-8 cycloalkyls, C1-6 substituted alkyls, C3-8 substituted cycloalkyls, aryls substituted aryls, aralkyls, C1-6 heteroalkyls, substituted C1-6 heteroalkyls, C1-6 alkoxy, phenoxy and C1-6 heteroalkoxy;
R28 is selected from the group consisting of hydrogen, C1-6 alkyls, C3-12 branched alkyls, C3-8 cycloalkyls, C1-6 substituted alkyls, C3-8 substituted cycloalkyls, aryls substituted aryls, aralkyls, C1-6 heteroalkyls, substituted C1-6 heteroalkyls, C1-6 alkoxy, phenoxy and C1-6 heteroalkoxy, NO2, haloalkyl and halogen; and n and q are independently selected positive integers.
25. The compound of claim 1, wherein L2 is selected from the group consisting of:
(CH2)j (CH2CH2O)2(CH2)2NH, -NH(CH2CH2O)j(CH2)k NR29-, -NH(CH2CH2O)j-, -NH(CR30R31)j O-, -C(O)(CR30R31)j NHC(O)(CR32R33)j NR29-, -C(O)O(CH2)k O-, -C(O)(CR30R31)j NR29-, -C(O)NH(CH2CH2O)j(CH2)k NR29-, -C(O)O-(CH2CH2O)j NR29-, -C(O)NH(CR30R31)j O-, -C(O)O(CR30R31)j O-, -C(O)NH(CH2CH2O)j-, wherein R29-33 are independently selected from the group consisting of hydrogen, C1-6 alkyls, C3-12 branched alkyls, C3-8 cycloalkyls, C1-6 substituted alkyls, C3-8 substituted cycloalkyls, aryls substituted aryls, aralkyls, C1-6 heteroalkyls, substituted C1-6 heteroalkyls, C1-6 alkoxy, phenoxy and C1-6 heteroalkoxy;
R34 is selected from the group consisting of hydrogen, C1-6 alkyls, C3-12 branched alkyls, C3-8 cycloalkyls, C1-6 substituted alkyls, C3-8 substituted cycloalkyls, aryls substituted aryls, aralkyls, C1-6 heteroalkyls, substituted C1-6 heteroalkyls, C1-6 alkoxy, phenoxy and C1-6 heteroalkoxy, NO2, haloalkyl and halogen; and j and k are independently selected positive integers.
(CH2)j (CH2CH2O)2(CH2)2NH, -NH(CH2CH2O)j(CH2)k NR29-, -NH(CH2CH2O)j-, -NH(CR30R31)j O-, -C(O)(CR30R31)j NHC(O)(CR32R33)j NR29-, -C(O)O(CH2)k O-, -C(O)(CR30R31)j NR29-, -C(O)NH(CH2CH2O)j(CH2)k NR29-, -C(O)O-(CH2CH2O)j NR29-, -C(O)NH(CR30R31)j O-, -C(O)O(CR30R31)j O-, -C(O)NH(CH2CH2O)j-, wherein R29-33 are independently selected from the group consisting of hydrogen, C1-6 alkyls, C3-12 branched alkyls, C3-8 cycloalkyls, C1-6 substituted alkyls, C3-8 substituted cycloalkyls, aryls substituted aryls, aralkyls, C1-6 heteroalkyls, substituted C1-6 heteroalkyls, C1-6 alkoxy, phenoxy and C1-6 heteroalkoxy;
R34 is selected from the group consisting of hydrogen, C1-6 alkyls, C3-12 branched alkyls, C3-8 cycloalkyls, C1-6 substituted alkyls, C3-8 substituted cycloalkyls, aryls substituted aryls, aralkyls, C1-6 heteroalkyls, substituted C1-6 heteroalkyls, C1-6 alkoxy, phenoxy and C1-6 heteroalkoxy, NO2, haloalkyl and halogen; and j and k are independently selected positive integers.
26. A compound of claim 1, selected from the group consisting of
27. A compound of claim 1, selected from the group consisting of
28. A method of preparing a camptothecin analog, comprising:
a) reacting a camptothecin derivative of the formula:
wherein:
R1 is selected from the group consisting of amino acid residues, peptide residues containing from about 2 to about 10 amino acids, Y3-(L2)P-A2 and R2;
Y3 is O, S or NR3;
p is zero or one;
L2 is a bifunctional linker;
A2 is selected from the group consisting of hydrogen, amino protecting groups, NR8R9, amino acid residues, peptide residues containing from about 2 to about 10 amino acids; polymeric residues, R10, SR11, NC(O)R12;
D3-D7 are independently selected from the group consisting of H, C1-8 straight or branched alkyls, substituted C1-8 straight or branched alkyls, aryls, substituted aryls, arylalkyls, substituted aryalkyls, C1-8 alkyl aryls, C1-8 alkoxys, C1-8 hydroxyalkyls, C1-8 aminoalkoxy, aryloxys, gycals, CO2R13, R14, nitro, cyano, halo, hydroxyl, amino, SR15, NR16R17 or OR18, where D4 and D5 optionally, when taken together, form a saturated 3-7 membered heterocyclic ring which may contain O, S or NR19 groups, where R19 is hydrogen or a C1-6 alkyl;
D8-D10 are independently selected from the group consisting of H, C1-8 straight or branched alkyls, substituted C1-8 straight or branched alkyls, aryls, substituted aryls, arylalkyls, substituted aryalkyls, C1-8 alkylaryls and C1-8 hydroxyalkyls; and R2-18 are independently selected from the group consisting of hydrogen, C1-6 alkyls, C3-19 branched alkyls, C3-8 cycloalkyls, C1-6 substituted alkyls, C3-8 substituted cyloalkyls, aryls, substituted aryls, aralkyls, C1-6 heteroalkyls, substituted C1-6 heteroalkyls, C1-6 alkoxy, phenoxy and C1-6 heteroalkoxy;
with a blocked bifunctional spacer to form a protected intermediate, and b) deprotecting said protected intermediate and reacting the resultant deprotected intermediate with an activated polymer under conditions sufficient to cause a polymeric conjugate to be formed.
a) reacting a camptothecin derivative of the formula:
wherein:
R1 is selected from the group consisting of amino acid residues, peptide residues containing from about 2 to about 10 amino acids, Y3-(L2)P-A2 and R2;
Y3 is O, S or NR3;
p is zero or one;
L2 is a bifunctional linker;
A2 is selected from the group consisting of hydrogen, amino protecting groups, NR8R9, amino acid residues, peptide residues containing from about 2 to about 10 amino acids; polymeric residues, R10, SR11, NC(O)R12;
D3-D7 are independently selected from the group consisting of H, C1-8 straight or branched alkyls, substituted C1-8 straight or branched alkyls, aryls, substituted aryls, arylalkyls, substituted aryalkyls, C1-8 alkyl aryls, C1-8 alkoxys, C1-8 hydroxyalkyls, C1-8 aminoalkoxy, aryloxys, gycals, CO2R13, R14, nitro, cyano, halo, hydroxyl, amino, SR15, NR16R17 or OR18, where D4 and D5 optionally, when taken together, form a saturated 3-7 membered heterocyclic ring which may contain O, S or NR19 groups, where R19 is hydrogen or a C1-6 alkyl;
D8-D10 are independently selected from the group consisting of H, C1-8 straight or branched alkyls, substituted C1-8 straight or branched alkyls, aryls, substituted aryls, arylalkyls, substituted aryalkyls, C1-8 alkylaryls and C1-8 hydroxyalkyls; and R2-18 are independently selected from the group consisting of hydrogen, C1-6 alkyls, C3-19 branched alkyls, C3-8 cycloalkyls, C1-6 substituted alkyls, C3-8 substituted cyloalkyls, aryls, substituted aryls, aralkyls, C1-6 heteroalkyls, substituted C1-6 heteroalkyls, C1-6 alkoxy, phenoxy and C1-6 heteroalkoxy;
with a blocked bifunctional spacer to form a protected intermediate, and b) deprotecting said protected intermediate and reacting the resultant deprotected intermediate with an activated polymer under conditions sufficient to cause a polymeric conjugate to be formed.
29. A method of preparing a polymer conjugate, comprising a) reacting a compound of the formula wherein:
D3 -D7 are independently selected from the group consisting of H, C1-8 straight or branched alkyls, substituted C1-8 straight or branched alkyls, aryls, substituted aryls, arylalkyls, substituted aryalkyls, C1-8 alkylaryls, C1-8 alkoxys, C1-8 hydroxyalkyls, C1-8 aminoalkoxy, aryloxys, gycals, CO2R13R14, nitro, cyano, halo, hydroxyl amino, SR15, NR16R17 or OR18, where D4 and D5 optionally, when taken together, form a saturated 3-7 membered heterocyclic ring which may contain O, S or NR19 groups, where R19 is hydrogen or a C1-6 alkyl;
D8-D10 are independently selected from the group consisting of H, C1-8 straight or branched alkyls, substituted C1-8 straight or branched alkyls, aryls, substituted aryls, arylalkyls, substituted aryalkyls, C1-8 alkylaryls and C1-8 hydroxyalkyls; and R8-18 are independently selected from the group consisting of hydrogen, C1-6 alkyls, C3-19 branched alkyls, C3-8 cycloalkyls, C1-6 substituted alkyls, C3-8 substituted cyloalkyls, aryls, substituted aryls, aralkyls, C1-6 heteroalkyls, substituted C1-6 heteroalkyls, C1-6 alkoxy, phenoxy and C1-6 heteroalkoxy;
with a blocked bifunctional spacer in an inert solvent under conditions sufficient to open the E lactone and form a protected intermadiate of formula (VI) wherein R35 is a residue of a blocked bifunctional spacer;
b) acylating the C17 OH of said protected intermediate, and c) deprotecting said protected intermediate and reacting at least about 2 equivalents of the resultant deblocked intermediate with an activated polymer under conditions sufficient to cause a polymeric conjugate to be formed.
D3 -D7 are independently selected from the group consisting of H, C1-8 straight or branched alkyls, substituted C1-8 straight or branched alkyls, aryls, substituted aryls, arylalkyls, substituted aryalkyls, C1-8 alkylaryls, C1-8 alkoxys, C1-8 hydroxyalkyls, C1-8 aminoalkoxy, aryloxys, gycals, CO2R13R14, nitro, cyano, halo, hydroxyl amino, SR15, NR16R17 or OR18, where D4 and D5 optionally, when taken together, form a saturated 3-7 membered heterocyclic ring which may contain O, S or NR19 groups, where R19 is hydrogen or a C1-6 alkyl;
D8-D10 are independently selected from the group consisting of H, C1-8 straight or branched alkyls, substituted C1-8 straight or branched alkyls, aryls, substituted aryls, arylalkyls, substituted aryalkyls, C1-8 alkylaryls and C1-8 hydroxyalkyls; and R8-18 are independently selected from the group consisting of hydrogen, C1-6 alkyls, C3-19 branched alkyls, C3-8 cycloalkyls, C1-6 substituted alkyls, C3-8 substituted cyloalkyls, aryls, substituted aryls, aralkyls, C1-6 heteroalkyls, substituted C1-6 heteroalkyls, C1-6 alkoxy, phenoxy and C1-6 heteroalkoxy;
with a blocked bifunctional spacer in an inert solvent under conditions sufficient to open the E lactone and form a protected intermadiate of formula (VI) wherein R35 is a residue of a blocked bifunctional spacer;
b) acylating the C17 OH of said protected intermediate, and c) deprotecting said protected intermediate and reacting at least about 2 equivalents of the resultant deblocked intermediate with an activated polymer under conditions sufficient to cause a polymeric conjugate to be formed.
30. A method of treating a topoisomerase I inhibitor- related disease m mammals, comprising administering an effective amount of a compound of claim 1 to a mammal in need of such treatment.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/147,168 | 2002-05-16 | ||
| US10/147,168 US6608076B1 (en) | 2002-05-16 | 2002-05-16 | Camptothecin derivatives and polymeric conjugates thereof |
| PCT/US2003/015526 WO2003097356A1 (en) | 2002-05-16 | 2003-05-16 | Camptothecin derivatives and polymeric conjugates thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2485006A1 true CA2485006A1 (en) | 2003-11-27 |
Family
ID=27733658
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002485006A Abandoned CA2485006A1 (en) | 2002-05-16 | 2003-05-16 | Camptothecin derivatives and polymeric conjugates thereof |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US6608076B1 (en) |
| EP (1) | EP1503760A4 (en) |
| JP (1) | JP2005532429A (en) |
| AU (1) | AU2003232150A1 (en) |
| CA (1) | CA2485006A1 (en) |
| MX (1) | MXPA04011316A (en) |
| WO (1) | WO2003097356A1 (en) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6608076B1 (en) * | 2002-05-16 | 2003-08-19 | Enzon, Inc. | Camptothecin derivatives and polymeric conjugates thereof |
| US8394365B2 (en) | 2003-09-17 | 2013-03-12 | Nektar Therapeutics | Multi-arm polymer prodrugs |
| PL1675622T3 (en) * | 2003-09-17 | 2017-11-30 | Nektar Therapeutics | Multi-arm polymer prodrugs |
| WO2005070921A1 (en) * | 2004-01-23 | 2005-08-04 | Elan Pharmaceuticals, Inc. | Polyethylene glycol conjugates of heterocycloalkyl carboxamido propanoic acids |
| EP1877097B1 (en) * | 2004-08-11 | 2012-06-20 | Arqule, Inc. | Aminoacid conjugates of beta-lapachone for tumor targeting |
| US8614228B2 (en) | 2004-08-11 | 2013-12-24 | Arqule, Inc. | Quinone prodrug compositions and methods of use |
| US7612153B2 (en) * | 2004-10-25 | 2009-11-03 | Intezyne Technologies, Inc. | Heterobifunctional poly(ethylene glycol) and uses thereof |
| US7462627B2 (en) * | 2006-02-09 | 2008-12-09 | Enzon Pharmaceuticals, Inc. | Multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin for treatment of breast, colorectal, pancreatic, ovarian and lung cancers |
| US7671067B2 (en) * | 2006-02-09 | 2010-03-02 | Enzon Pharmaceuticals, Inc. | Treatment of non-hodgkin's lymphomas with multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamtothecin |
| KR101394768B1 (en) | 2006-03-30 | 2014-05-21 | 드라이스 파마슈티컬스 아이엔씨 | Camptothecin-cell penetrating peptide conjugates and pharmaceutical compositions containing the same |
| US7560588B2 (en) * | 2006-04-27 | 2009-07-14 | Intezyne Technologies, Inc. | Poly(ethylene glycol) containing chemically disparate endgroups |
| KR101441709B1 (en) * | 2006-11-30 | 2014-09-18 | 넥타르 테라퓨틱스 | Method for preparing a polymer conjugate |
| KR20090108082A (en) * | 2007-02-09 | 2009-10-14 | 엔존 파마슈티컬즈, 인코포레이티드 | Treatment of resistant or refractory cancers with multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin |
| WO2008134088A1 (en) * | 2007-04-30 | 2008-11-06 | Arqule, Inc. | Hydroxy sulfonate of quinone compounds and their uses |
| MX2011001583A (en) | 2008-08-11 | 2011-04-04 | Nektar Therapeutics | Multi-arm polymeric alkanoate conjugates. |
| WO2010025337A1 (en) * | 2008-08-29 | 2010-03-04 | Enzon Pharmaceuticals, Inc. | Method of treating ras associated cancer |
| ES2744975T3 (en) | 2008-09-23 | 2020-02-27 | Nektar Therapeutics | Metronome dosage method with camptothecin prodrugs (eg PEG-Irinotecan) |
| WO2010048018A1 (en) * | 2008-10-21 | 2010-04-29 | Enzon Pharmaceuticals, Inc. | Treatment of neuroblastoma with multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin |
| EP3498754A1 (en) | 2009-11-18 | 2019-06-19 | Nektar Therapeutics | Alkoxylation methods |
| WO2012088422A1 (en) | 2010-12-22 | 2012-06-28 | Nektar Therapeutics | Multi-arm polymeric prodrug conjugates of taxane-based compounds |
| WO2012088445A1 (en) | 2010-12-22 | 2012-06-28 | Nektar Therapeutics | Multi-arm polymeric prodrug conjugates of cabazitaxel-based compounds |
| LT3141542T (en) | 2011-12-28 | 2020-09-25 | Global Blood Therapeutics, Inc. | Substituted benzaldehyde compounds and methods for their use in increasing tissue oxygenation |
| ES2790358T3 (en) | 2011-12-28 | 2020-10-27 | Global Blood Therapeutics Inc | Substituted Heteroaryl Aldehyde Compounds and Methods for Their Use in Increasing Tissue Oxygenation |
| US9802900B2 (en) | 2013-03-15 | 2017-10-31 | Global Blood Therapeutics, Inc. | Bicyclic heteroaryl compounds and uses thereof for the modulation of hemoglobin |
| KR20150132146A (en) | 2013-03-15 | 2015-11-25 | 글로벌 블러드 테라퓨틱스, 인크. | Compounds and uses thereof for the modulation of hemoglobin |
| KR102293060B1 (en) | 2013-03-15 | 2021-08-23 | 글로벌 블러드 테라퓨틱스, 인크. | Compounds and uses thereof for the modulation of hemoglobin |
| US9604999B2 (en) | 2013-03-15 | 2017-03-28 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| US10266551B2 (en) | 2013-03-15 | 2019-04-23 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| US9422279B2 (en) | 2013-03-15 | 2016-08-23 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| US9458139B2 (en) | 2013-03-15 | 2016-10-04 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| US8952171B2 (en) | 2013-03-15 | 2015-02-10 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| US20140274961A1 (en) | 2013-03-15 | 2014-09-18 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| US10100043B2 (en) | 2013-03-15 | 2018-10-16 | Global Blood Therapeutics, Inc. | Substituted aldehyde compounds and methods for their use in increasing tissue oxygenation |
| AP2015008721A0 (en) | 2013-03-15 | 2015-09-30 | Global Blood Therapeutics Inc | Compounds and uses thereof for the modulation of hemoglobin |
| EA201992707A1 (en) | 2013-11-18 | 2020-06-30 | Глобал Блад Терапьютикс, Инк. | COMPOUNDS AND THEIR APPLICATIONS FOR HEMOGLOBIN MODULATION |
| CN114181194A (en) | 2014-02-07 | 2022-03-15 | 全球血液疗法股份有限公司 | Crystalline polymorph of a compound |
| MA41841A (en) | 2015-03-30 | 2018-02-06 | Global Blood Therapeutics Inc | ALDEHYDE COMPOUNDS FOR THE TREATMENT OF PULMONARY FIBROSIS, HYPOXIA, AND AUTOIMMUNE AND CONNECTIVE TISSUE DISEASES |
| EP3383392A1 (en) | 2015-12-04 | 2018-10-10 | Global Blood Therapeutics, Inc. | Dosing regimens for 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde |
| TWI752307B (en) | 2016-05-12 | 2022-01-11 | 美商全球血液治療公司 | Novel compound and method of preparing compound |
| TW202332423A (en) | 2016-10-12 | 2023-08-16 | 美商全球血液治療公司 | Tablets comprising 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde |
| EP3860975B1 (en) | 2018-10-01 | 2023-10-18 | Global Blood Therapeutics, Inc. | Modulators of hemoglobin for the treatment of sickle cell disease |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1332413C (en) | 1987-06-25 | 1994-10-11 | Kabushiki Kaisha Yakult Honsha | Camptothecin derivatives and process for preparing same |
| US5552154A (en) | 1989-11-06 | 1996-09-03 | The Stehlin Foundation For Cancer Research | Method for treating cancer with water-insoluble s-camptothecin of the closed lactone ring form and derivatives thereof |
| JP4094710B2 (en) * | 1997-11-06 | 2008-06-04 | 株式会社ヤクルト本社 | New camptothecin derivatives |
| US6608076B1 (en) * | 2002-05-16 | 2003-08-19 | Enzon, Inc. | Camptothecin derivatives and polymeric conjugates thereof |
-
2002
- 2002-05-16 US US10/147,168 patent/US6608076B1/en not_active Expired - Fee Related
-
2003
- 2003-05-16 MX MXPA04011316A patent/MXPA04011316A/en active IP Right Grant
- 2003-05-16 EP EP03753067A patent/EP1503760A4/en not_active Ceased
- 2003-05-16 JP JP2004504726A patent/JP2005532429A/en active Pending
- 2003-05-16 AU AU2003232150A patent/AU2003232150A1/en not_active Abandoned
- 2003-05-16 WO PCT/US2003/015526 patent/WO2003097356A1/en active Application Filing
- 2003-05-16 CA CA002485006A patent/CA2485006A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2003097356A1 (en) | 2003-11-27 |
| EP1503760A4 (en) | 2007-10-31 |
| US6608076B1 (en) | 2003-08-19 |
| EP1503760A1 (en) | 2005-02-09 |
| WO2003097356A9 (en) | 2004-11-11 |
| AU2003232150A1 (en) | 2003-12-02 |
| JP2005532429A (en) | 2005-10-27 |
| AU2003232150A8 (en) | 2003-12-02 |
| MXPA04011316A (en) | 2005-08-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2485006A1 (en) | Camptothecin derivatives and polymeric conjugates thereof | |
| JP4860813B2 (en) | Terminally branched polymer linker and polymer conjugate containing the same | |
| CA2263409C (en) | High molecular weight polymer-based prodrugs | |
| CA2493329C (en) | Releasable polymeric conjugates based on aliphatic biodegradable linkers | |
| CA2517459C (en) | Heterobifunctional polymeric bioconjugates | |
| US7462627B2 (en) | Multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin for treatment of breast, colorectal, pancreatic, ovarian and lung cancers | |
| US6777387B2 (en) | Terminally-branched polymeric linkers containing extension moieties and polymeric conjugates containing the same | |
| US20090203706A1 (en) | Lysine-based polymeric linkers | |
| AU2007212201B2 (en) | Multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin for treatment of breast, colorectal, pancreatic, ovarian and lung cancers | |
| CA2383240A1 (en) | Polymer conjugates of ara-c and ara-c derivatives | |
| JP2010536986A (en) | Polymer linker containing a pyridyl disulfide moiety | |
| US6756037B2 (en) | Polymer conjugates of biologically active agents and extension moieties for facilitating conjugation of biologically active agents to polymeric terminal groups | |
| WO2009009716A1 (en) | Polymeric drug delivery systems containing an aromatic allylic acid | |
| CA2336663C (en) | Coumarin and related aromatic-based polymeric prodrugs | |
| CA2479810A1 (en) | Polymeric acyl derivatives of indoles | |
| IL301558A (en) | Peptidic conjugates of sn38 useful in the treatment of cancer | |
| WO2004044223A2 (en) | Prodrugs of vancomycin with hydrolysis resistant polymer linkers | |
| JP2009539879A (en) | Indenoisoquinoline-releasing polymer composite |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued |